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ABSTRACT

The mechanistic Target of Rapamycin Complex 1 (mTORC1) pathway
integrates cellular availability of growth factors, energy and amino acids to regulate
protein synthesis and autophagy. The mTORC1 pathway has also been shown to be
required for memory consolidation, and its dysregulation is associated with many
neurological disorders. MTORC1 is negatively regulated by the tuberous sclerosis
complex (TSC1/2). When ATP and growth factors are available, TSC1/2 is inhibited
and mTORC1 activity can be restored. In a complementary regulatory pathway, amino
acids signal to mTORC1 through the Rag GTPases and Ragulator complex, which
modulate the translocation of mTORC1 from the cytoplasm to the lysosomal surface
where activation occurs. This thesis investigates the role of mTORC1 in memory
formation and dysfunction.
It has been shown that in response to traumatic brain injury (TBI), mTORC1
activity is acutely increased, and treatment with rapamycin, a specific inhibitor of
mTORC1, has been shown to improve outcome. On the other hand, chronic elevated
levels of mTORC1 are required for axonal regeneration of injured peripheral nerves
and increased synapse growth after TBI. These results suggest that this mTORC1
could be a potential therapeutic target for TBI patients, but it remains unclear whether
inhibition or activation of mTORC1 would improve outcome. Using a TSC2 knock-out
viii

mouse model we investigated the effects of elevated mTORC1 activity on outcome
using hippocampal-dependent learning and memory tasks. My results suggest that
acute overactivation of mTORC1 impairs long-term memory after brain injury and its
return to baseline is associated with recovery. These results could aid in the design of
treatments for brain-injured patients that differentially target the mTORC1 pathway in a
temporally specific manner following brain trauma.
In vitro studies have shown that the amino acid glutamine decreases, while
leucine increases, mTORC1 signaling in amino acid deprived cells.

However, it

remains unclear if glutamine and leucine would be effective in vivo at modulating
mTORC1 signaling in the brain in order to influence cognition. My results show that in
vivo intrahippocampal infusions of glutamine inhibited mTORC1 signaling and
impaired memory formation, effects that were reversed by the co-administration of
leucine. Furthermore, oral administration of glutamine to conditional knock-out mice
lacking the Tsc2 gene prolonged their survival. Taken together, these findings indicate
that glutamine can decrease brain mTORC1 activity, and may have utility in the
treatment of neurological problems associated with elevated mTORC1 signaling.
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CHAPTER 1

Introduction

1

THE MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY

Humans have searched nature for medicinal products for at least 5000 years
(152). Discovering new drugs to treat incurable diseases and improve health drives
the quest to find new organic compounds from plants, bacteria, fungi or animals even
today.

The story of the mechanistic Target of Rapamycin (mTOR) starts with a

Canadian expedition to Easter Island in the 1960s.

This excursion’s goal was to

collect soil and plant samples to be analyzed later for drug discovery (122).
Fortuitously, the bacterium Streptomyces hygroscopicus was found in one of these soil
samples.

This bacterium produces a secondary metabolite with strong antifungal

properties. Researchers decided to name this metabolite “Rapamycin” in honor of the
place it was found1 (173, 194).
Interestingly, the original anti-fungal property of rapamycin turned out to be only
one of its many potential uses.

Rapamycin earned a special appreciation as an

immunosuppressant and anti-cancer drug due to its capacity to inhibit cell growth and
division. However, a target of rapamycin was yet to be found (75, 129). Sixteen years
after the first rapamycin research publications, a group of scientists in Switzerland
discovered the first evidence for the molecular targets of rapamycin. They searched
for spontaneous yeast mutants able to grow in concentrations of rapamycin known to
halt cellular division. Two mutants were found with dominant resistance to rapamycin
and researches designated them Target of Rapamycin 1 (TOR1) and TOR2. These
genes

were

later

cloned

and

sequenced

to

discover

that

they encoded

phosphatidylinositol-like kinases (16, 108). A year later, the mammalian homologue
1

“Rapa Nui” means Easter Island in the native language and “mycin” is the latin form to name
drugs derived from a fungus-like bacteria
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TOR protein was described (13, 163).

It is now known that TOR kinases are

conserved in most eukaryotes, with metazoans carrying only one TOR gene. We also
know that even though they resemble phosphatidylinositol kinases, they are truly
serine/threonine protein kinases. Results from the last 20 years of TOR research
suggest that this pathway impacts many critical cellular functions, including playing a
leading role in the regulation of cell growth and proliferation. These functions have
associated TOR signaling with memory consolidation and plasticity. Furthermore, the
observation that TOR signaling is dysregulated in many human diseases, including
neurological disorders, has motivated the search for ways to modulate activity of this
pathway and inspired this thesis work.

In this chapter, I will review our current

understanding of TOR signaling, with an emphasis on its role in memory function and
dysfunction.

MTOR kinase is part of the mTOR complex 1 signaling pathway

The mTOR kinase can be part of two distinct complexes: mTOR complex 1
(mTORC1) and mTORC2.

These two complexes differ from each other in their

sensitivity to rapamycin, regulation by upstream signals and downstream targets and
biological effects.

Acute rapamycin treatment inhibits mTOR when it is part of

mTORC1 but not mTORC2 (83, 123). The lack of a specific inhibitor of mTORC2 has
limited the knowledge about this pathway.

It is known that growth factors act as

upstream regulators of mTORC2, but their mechanism of action and whether other
signals regulate this pathway is not known (154). MTORC2 regulates cell survival and
cytoskeletal organization through its action on Akt (also known as protein kinase B)
3

and protein kinase Cα respectively. Akt is an important oncogene mutated in several
types of cancers and mTORC2 plays a major role in its phosphorylation and activation.
In addition, the role of mTORC2 in mediating cytoskeletal organization has implicated
this pathway in tumor cell motility and metastasis (168, 210). Recently, it was shown
that mTORC2 is involved in memory formation. A conditional brain deletion of a key
protein found in mTORC2 decreased actin polymerization in the hippocampus and
impaired long-term memory (LTM) and late-phase hippocampal long-term potentiation
(L-LTP) (78). MTORC1, on the other hand, integrates several cellular signals derived
from growth factor, energy and nutrient availability to regulate macromolecule
biosynthesis, autophagy and energy metabolism. The role of mTORC1 in regulating
protein synthesis suggests this pathway influences neuronal plasticity and memory
formation (26). In addition, its role as an autophagy inhibitor has associated mTORC1
with several neurodegenerative disorders (22, 23). In the remaining sections I will
focus my attention on the mTORC1 pathway.
The

mTOR

protein

is

a

serine/threonine

phosphoinositide 3-kinase (PI3K)-related kinase family.

kinase

belonging

to

the

Composed of 2549 amino

acids, mTOR contains five major domains (Fig 1.1) (112). Near the N-terminus, there
are several HEAT repeats (present in: Huntingtin, Elongation factor 3, protein
phosphatase 2A, TOR), which are thought to act as flexible scaffolding for other
proteins to attach. Indeed, a protein named regulatory-associated protein of mTOR
(raptor) binds mTOR at the HEAT domain to regulate assembly, localization and
substrate binding to mTORC1. Raptor is one of the defining components of mTORC1,
by interacting with certain substrates that contain a TOR signaling motif; it determines

4

the specificity of mTORC1 (63, 97). mTOR also contains two domains found in all
PI3K-related protein subfamilies: a FAT domain (present in PI3K-related protein

Figure 1.1: Components of mTORC1 in relation to mTOR protein domain structure.
mTOR protein (blue) depicting its five major domains: HEAT, FAT, FRB, Kinase and
FATC. The mTOR protein together with raptor, deptor, mLST8, PRAS40, tti1 and tel2
form the mTOR complex 1. The Rapamycin-FKBP12 complex specifically interacts
with mTOR and acutely inhibits it only when it is part of mTORC1.

subfamilies: FRAP, ATP, TRRAP) and a FATC domain (FAT COOH-terminus) which
are essential for kinase function (12, 181). It is thought that FAT and FATC interact in
a way in which they can expose the catalytic domain. Supporting this view, deptor
(DEP domain-containing mTOR-interacting protein) acts as an inhibiting regulator of
mTORC1 and binds mTOR through the FAT domain (151). The mechanism by which
5

rapamycin inhibits mTORC1 is not yet fully understood, but it is known that the
intracellular FK506-binding protein (FKBP12) first binds rapamycin, and then together
they interact and inhibit mTOR through its FKBP12-rapamycin-binding domain (FRB)
(13, 163). Finally, the mTOR kinase domain shares some sequence similarity to PI3K,
though it is functionally distinct, as it confers serine/threonine specific, rather than
phosphatidylinositol, kinase activity.
Seven core proteins are known to compose mTORC1: mTOR, raptor, deptor,
proline-rich AKT substrate of 40kDa (PRAS40) and SEC13 protein 8 (mLST8),
telomere maintenance 2 (tel2) and Tel2-interacting protein (tti1) (112).

Studies

suggest that PRAS40, like deptor, acts as an mTORC1 inhibitor. Both PRAS40 and
deptor are also substrates for mTOR kinase, and when phosphorylated by active
mTOR, their association with the complex is weakened, promoting further mTOR
kinase activity (167, 186, 193, 196).

The role of mLST8 is still unclear since its

deletion has no effect on mTORC1 activity (59, 98). When Tti1 and tel2 are depleted,
mTOR complex formation and stability is impaired suggesting they may play a role as
scaffolding proteins (94).

The wide range of processes that mTORC1 regulates

suggests it may be reasonable to think that additional proteins that interact with
mTORC1 are yet to be found. The identification of novel proteins associated with
mTORC1 could aid our understanding by providing insights into mTORC1 target
specificity, function and regulation.

6

Upstream regulation of mTORC1

Most cellular signals that reach mTORC1 are known to travel through either of
two ways: growth factors and ATP levels through the tuberous sclerosis complex 1/2
(TSC1/2), or amino acids through the Rag GTPases. Directly upstream of mTOR, Ras
homologue enriched in brain GTPase (Rheb) interacts and strongly stimulates
mTORC1 activity. TSC1/2, a GTPase activating protein (GAP) complex, formed by
tuberous sclerosis complex 1 (TSC1 also called hamartin), TSC2 (also called tuberin)
and Tre2-Bub2-Cdc16 (TBC), is responsible for converting Rheb into its inactive GDPbound state (36, 53, 124). Therefore, when upstream input is lacking, TSC1/2 keeps
Rheb in its GDP-bound state and mTORC1 is inhibited (Figure 1.2A). Growth factors,
stress signals, oxygen and energy levels are sensed through a vast network of
signaling pathways that converge on TSC1/2. For instance, insulin (a nutrient signal
produced in response to increased blood glucose levels) can bind to receptor tyrosine
kinases on the cell surface and activate the PI3K-Akt pathway which leads to TSC1/2
inactivation and subsequent mTORC1 activation by GTP-bound Rheb. Other growth
factors follow a similar pathway to reach mTORC1 or signal through the Ras-Erk
pathway instead (37). Energy status, by way of a change in the AMP:ATP ration, can
be sensed by the AMP-dependent protein kinase (AMPK). When AMPK is active, it
phosphorylates and activates TSC1/2 to inhibit mTORC1 activity (34, 150).
Altogether, mTORC1 is a major regulator of anabolic processes that receives most
cellular inputs regarding energy and nutrient availability through TSC1/2.
Amino acids also play a major role in mTORC1 signaling. In their absence,
growth factor and energy signals are unable to activate mTORC1. In vitro studies
7
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(On previous page)

Figure 1.2: Upstream regulation of mTORC1. A) Amino acid insufficiency fails to
activate v-ATPase and ragulator. These networks are involved in the activation and
anchoring of the Rag proteins to the lysosomal membrane. RagA/B remain in their
GDP-bound forms unable to bind mTORC1 for translocation to the lysosomal
membrane where Rheb is located. A lack of cellular nutrient and energy availability
promote the activation of TSC1/2 which inhibits Rheb through its GAP activity. GDPbound Rheb is unable to interact with mTORC1 to stimulate its kinase activity. B)
Upon growth factor availability and increased ATP levels, TSC1/2 becomes repressed
and consequently its inhibition on Rheb is terminated. GTP-bound Rheb is then ready
to interact and promote mTORC1 activity.

However, amino acids are required to

promote v-ATPase and ragulator, which in turn activate and anchor Rag proteins to
the lysosomal membrane bringing mTORC1 to the site for Rheb to complete its
activation.
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suggest that mTORC1 is exceptionally sensitive to the levels of certain amino acids,
particularly leucine, arginine and glutamine.

Although an intracellular amino acid

sensor has yet to be identified, it has been shown that the Ragulator complex and Rag
GTPases (RagA, B, C and D) play an important role in this process (85).

Rag

GTPases are small G proteins able to form heterodimers: RagA or B with RagC or D.
These heterodimers have been found to have opposite nucleotide loading states.
When amino acids are absent RagA/B is GDP-bound and RagC/G is GTP-bound, this
makes the complex inactive. Rag GTPases seem to work in parallel to Rheb and upon
amino acid availability; RagA/B become GTP-bound (And RagC/D GDP-bound). This
is promoted by the Ragulator complex, which acts as a guanine nucleotide exchange
factor for RagA and B and promotes GDP release for subsequent loading with GTP
(Figure 1.2A and B) (99, 165, 166). While growth factors and energy signals converge
at TSC1/2, to regulate Rheb, amino acids stimulate Ragulator and Rag GTPases to
induce the translocation of mTORC1 from the cytoplasm to the lysosomal surface.
Interestingly, the lysosomal surface is one of the places where active Rheb can be
found. Constitutive expression of GTP-bound RagA and B, which anchor mTORC1
near Rheb, make mTORC1 activation resistant to amino acid starvation (165). This
supports the current thinking that the coordinated shift of mTORC1 localization
towards Rheb ensures mTORC1 activation only when amino acids are available.
Therefore, one could potentially inhibit mTORC1 signaling through either of these two
parallel mechanisms: TSC1/2 or Rag-Ragulator networks.
Recent studies have focused their attention on the characterization of Vacuolar
H+-ATPase (v-ATPase) and its role in mTORC1 regulation upon amino acid
availability. v-ATPase is found in the lysosomal membrane and pumps protons into
10

the organelle to decrease pH. Interestingly, v-ATPase interacts with both the ragulator
complex and Rag proteins under conditions of amino acid starvation. An increase in
amino acids (intracellular and/or extracellular) leads to their accumulation inside the
lysosome and communicates to v-ATPase ultimately leading to mTORC1 activation.
This has been suggested as the “inside-out” mechanism of amino acid regulation of
mTORC1 (211). Whether v-ATPase can directly sense amino acids is not known.
Leucine and Arginine are known to be the best mTORC1 activators, since depriving
cells from either one of them closely resembles complete amino acid starvation (65).
These amino acids likely signal to mTORC1 through the Rag-Ragulator pathway
although the mechanism by which cells sense these amino acids is not fully
understood.

Leucyl-tRNA synthetase (LeuRS) has been suggested as a potential

leucine sensor. LeuRS is a cytoplasmic protein that can catalyze the ATP-dependent
ligation of L-leucine to the corresponding tRNA. When leucine is available, LeuRS
translocates to the lysosomal membrane and can act as a GAP for RagD (11, 62).
However, in contrast to the “inside-out” model for amino acid detection, LeuRS senses
leucine availability in the cytoplasm. Further studies will be needed to understand if,
and how, these two leucine sensing models cooperate to regulate mTORC1.
Glutamine is a non-essential amino acid abundant in the blood stream and
involved in several biological functions critical for cell growth. Glutamine can enter the
Krebs cycle by producing α-ketoglutarate through glutaminolysis.

It is also

incorporated into proteins during translation and is necessary for amino acid, fatty acid
and nucleotide synthesis. Glutamine participates in the glutamine-glutamate-GABA
cycle, thus playing an important part in neurotransmitter recycling in the brain.
Interestingly, glutamine has also been shown to modulate mTORC1 activity, although
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the mechanisms of action are not fully understood (102). It has been proposed that
glutamine is a key component of leucine-induced mTORC1 activation. When cultured
HeLa cells are deprived of amino acids, adding only the essential amino acids back
into the culture media does not fully activate mTORC1. When both, essential amino
acids and glutamine, are incorporated to the culture they synergize to stimulate
mTORC1. Systematic inhibition of the amino acid transporters SLC1A5 and SLC7A5
led Nicklin et al. to propose a mechanism by which intracellular glutamine is
exchanged for extracellular leucine to activate mTORC1 (140).

This finding was

independent of glutamine derived-glutamate or α-ketoglutarate, suggesting that
glutamine acts as a free amino acid to indirectly modulate mTORC1. However, this
does not seem to be the only mechanism for mTORC1 activation by glutamine.
Inhibition of glutaminolysis was shown to reduce GTP-RagB, which in turn blocked
mTORC1 translocation to the lysosome and activation in response to glutamine and
leucine (39). Furthermore, addition of an α-ketoglutarate analogue restored mTORC1
translocation and its subsequent activation (39).

Interestingly, during glucose and

glutamine starvation, adding Krebs cycle intermediates (α-ketoglutarate from
glutamine, pyruvate from glucose) can restore mTORC1 activation through an AMPK
and Rag independent pathway. The model proposed suggests that the scaffolding
proteins tti1 and tel2, together with tti2 and RuvB-like1 and 2, form a complex that
requires ATP to assemble and stabilize mTORC1 (103).

In summary, glutamine

appears to be able to indirectly regulate mTORC1 as a free amino acid promoting
leucine intake, or by providing Krebs cycle metabolites (called anaplerosis) through
glutaminolysis.
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Cells live in a complex nutritional environment that is in constant flux, mTORC1
is a key pathway able to integrate these signals in a timely manner to regulate
necessary anabolic processes. Although significant progress has been made towards
understanding the complexity of mTORC1 signaling, important questions remain
unanswered.

For example, experiments investigating amino acid regulation of

mTORC1 have been performed in starved cells that are systematically re-fed to
observe changes in biochemical interactions. Complete cellular and tissue starvation
is an unlikely situation when studying whole living organisms.

One hypothesis to

examine would be, if amino acid starvation and re-feeding strongly modulates
mTORC1 activity, then partial removal or addition of amino acids will regulate
mTORC1 in a graded manner. The confirmation of this hypothesis would suggest that
amino acids could have the potential to act not only as building blocks for proteins, but
also as signaling molecules. Moreover, understanding how different amounts of amino
acids finely modulate mTORC1 signaling could aid in the design of dietary treatments
for diseases in which this pathway becomes dysregulated.

MTORC1 downstream effects

When mTORC1 integrates information about the nutritional and energy status
of the cell, it is able to regulate major pathways leading to cellular growth and
proliferation.

The best characterized process regulated by mTORC1 is protein

synthesis. Translation consumes a great amount of nutrients and energy, and its
regulation is necessarily tied to mechanisms that are able to sense the cellular
environment for sources of nourishment. MTORC1 is one such mechanism, able to
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control protein synthesis through its kinase activity by direct or indirect phosphorylation
events.
Translation initiation starts when the small ribosome subunit is recruited to the
5’ end of the mRNA.

This recruitment is accomplished by eukaryotic translation

initiation factor 4E (eIF4E), a cap binding protein that binds the mRNA and promotes
the formation of the pre-initiation complex (eIF4F complex) containing eIF4E, eIF4G
(scaffold protein) and eIF4A (RNA helicase).

This complex recruits the small

ribosomal subunit to the mRNA to start scanning for the start codon. Once found, the
complete ribosome is assembled to begin polypeptide formation (54).

MTORC1

primarily regulates 5’ terminal oligopyrimidine (TOP) mRNAs through 4E(eIF4E)binding protein 1 (4E-BP1). 4E-BP1 is a translation initiation repressor that binds
eIF4E and prevents complex assembly.

MTORC1 promotes translation by

phosphorylating and inhibiting 4E-BP1, thus enabling translation initiation (Fig 1.3A)
(64, 64, 65, 65, 187). A second well characterized target of mTORC1 is S6 kinase
(S6K). When mTORC1 phosphorylates and activates S6K, they work in concert to
promote assembly of the translation pre-initiation complex (Fig 1.3A). For instance,
S6K phosphorylates eIF4B, a co-factor that enhances eI4FA helicase activity
necessary for translation initiation of double stranded 5’ untranslated regions of the
mRNA. S6K is able to phosphorylate and target for degradation programmed cell
death 4 (PDCD4), which inhibits eiF4A helicase activity (126, 130). S6K has also
been suggested to have a role in ribosome biogenesis thereby helping translation
efficiency (84). The ribosomal protein S6 (S6) was the first described target of S6K. It
is a component of the small ribosomal subunit and has been extensively used to study
mTORC1 activity even though its role in protein translation remains unclear (126, 127).
14

Protein synthesis is a paramount cellular process regulated throughout life. It plays
major roles in embryonic development, normal physiology maintenance and memory
formation. MTORC1 is a key pathway involved in translation activation upon nutrient
and energy availability making it an attractive pathway to study in diseases in which
polypeptide biogenesis is deregulated.

Figure 1.3: Simplified mTORC1 regulation of translation and autophagy. A) MTORC1
kinase directly phosphorylates 4E-BP1 inhibiting its repression of translation initiation.
It also phosphorylates S6K to promote protein synthesis in several ways, including
translation initiation complex formation. Levels of phosphorylated S6 are commonly
used as an indirect measure of mTORC1 activity. B) Active mTORC1 phosphorylates
ULK1 and Atg13 preventing their association for autophagosome formation.

15

The synthesis of lipids, upregulation of cellular metabolism and ATP production
are also anabolic processes that are influenced by mTORC1.

These anabolic

processes are regulated by transcription factors which, in turn, are controlled directly
or indirectly by mTORC1.

For example, the sterol regulatory element-binding

protein1/2 (SREBP1/2) transcription factors control the expression of many genes
necessary for the synthesis of fatty acids and cholesterol.

Inhibition of mTORC1

prevents SREBP1/2 translocation to the nucleus and decreases the translation of
lipogenic genes (40, 111, 156). Similarly, mTORC1 activates the transcription and
translation of glycolytic gene regulators like Hypoxia inducible factor 1α (14, 79).
Cellular growth can be promoted both by positive regulation of anabolic
processes or inhibition of catabolic processes.

MTORC1 is also involved in the

repression of macroautophagy (here referred to as autophagy). Autophagy is the main
mechanism by which cells degrade dysfunctional components, such as organelles and
proteins, via lysosomes. The cell loads lysosomes through the formation and transport
of intracellular membrane vesicles called autophagosomes.

In normal conditions,

basal levels of autophagy are responsible to help maintain cellular homeostasis by
recycling long-lived or damaged proteins and organelles.

Autophagy levels can

increase in response to cellular stress, including starvation and growth factor
withdrawal. Similar to the regulation of protein synthesis, autophagy initiation is tightly
regulated to prevent unnecessary removal of healthy proteins but to rapidly react to
stress and degrade harmful components. In mammalian cells, the initiation complex of
the autophagy cascade contains Unc-51 Like autophagy activating Kinase 1 (ULK1),
Autophagy related 13 (Atg13) and RB1-inducible coiled-coil protein 1 (RB1CC1),
together making up the ULK1 complex (93, 203). Under normal conditions, ULK1 and
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Atg13 are phosphorylated on multiple sites that become dephosphorylated under
starvation conditions.

Several studies have shown that mTORC1 phosphorylates

ULK1 and Atg13 (Fig 1.3 B). These phosphorylation events correlate with autophagy
inhibition and lower ULK1 kinase activity. Additionally, rapamycin treatment reduces
the levels of phosphorylated ULK1 and Atg13 and increases ULK1 activity (52, 73, 93,
203). These studies suggest that mTORC1 is a key regulator of autophagy.
The mTORC1 complex has been linked to a wide range of disorders including
neurodegenerative disorders, traumatic brain injury (TBI), tuberous sclerosis complex
(TSC), age-related pathologies and metabolic diseases (38, 112, 128).

The

involvement of mTORC1 in several conditions is not surprising given that this pathway
is an important regulator of some of the most basic and necessary cellular functions.
Our understanding of mTORC1 signaling is still incomplete, but what is known can
guide future research to understand how different deregulated components give rise to
diverse diseases.

MTORC1 AND MEMORY FORMATION

Memory is one of the most complex mental processes in our body and can
define an individual. One of the biggest challenges of biology has been to understand
how different brain systems, cellular networks and molecular signaling pathways
interact together to encode, store and retrieve memories. More than 100 years ago,
two German scientists, Müller and Pilzecker, proposed the idea that memories took
time to be fixed. They called this process consolidation. They also suggested that
transient activity in the brain, acting as perseverations of the task being learned, was
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necessary for establishing representations and strengthening the associative memory
(113, 136). Around the same time, there was already a notion of short-term memories
(STM) and long-term memories (LTM). These concepts impacted Hebb’s seminal
theory in which he proposed that repeated excitation of one neuron onto a second,
would produce growth or metabolic changes conveying the first neuron the ability to
excite the second more efficiently (69).

Hebb proposed that new memories were

represented in “reverberating circuits”, the storage for STM.
reverberations, these STM would consolidate into LTM.

After enough

Hebb’s idea of changes

happening between neurons inspired the next generation of researchers to test
possible molecular mechanisms responsible for these alterations (113, 137).

A

popular strategy to elucidate some of the molecular pathways involved in synaptic
changes after memory formation has been to deliver different treatments immediately
after training. This approach can selectively target consolidation without altering either
acquisition or retrieval of memory. Early on, protein synthesis was found to be critical
for memory consolidation. Intracranial injections of puromycin (a protein synthesis
inhibitor) were shown to impair memory. It was also revealed that inhibition of memory
formation was possible only within a certain window of time after learning (9, 45, 177).
It is now known that memory can be divided into short-term memories, lasting
minutes to hours, and long-term memories lasting for years. Short-term memories do
not depend on protein synthesis, while long-term memories do.

Several different

studies have shown the importance of individual translational proteins in LTM
formation. For instance, when the interaction between components of the translation
initiation complex, eIF4E and eIF4G is disrupted in the amygdala, long-term fear
memory is impaired (72). Furthermore, genetically engineered mice lacking S6K show
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impaired learning and memory in diverse behavioral tasks including fear conditioning,
taste aversion and Morris water maze (7). It is then intuitive to think that mTORC1
also plays a role in the regulation of LTM through its ability to facilitate polypeptide
synthesis.

Indeed, Casadio et al.

showed that rapamycin impaired long-term

facilitation in Aplysia neurons (18). Later studies confirmed that inhibition of mTORC1
signaling, also utilizing rapamycin, could disrupt long-term memories in mammals (31,
183, 188).

In addition, LTM and L-LTP are associated with increased levels of

mTORC1 activity measured by downstream targets (including phospho-4E-BP1 and
phospho-S6K, and phospho-S6) (17, 175, 190).
Links between upstream regulators of mTORC1, such as growth factors and
energy levels, have also been shown to affect LTM. For instance, intra-hippocampal
infusions of glucose were shown to correlate with decreased AMPK activity, increased
mTORC1 activity and enhanced memory formation (31). On the other hand, inhibition
of AMPK with the AMP mimetic drug AICAR, activates AMPK, represses mTORC1
signaling and impairs LTM in rats and L-LTP in mouse hippocampal slices (31, 157).
In addition, brain-derived-neurotrophic-factor (BDNF) has been shown to induce
mTORC1 activation and translation in neuronal dendrites.

This suggests that

mTORC1 is also present at synaptic terminals and could contribute to the activation of
local protein synthesis required for L-LTP (95, 182).
memory formation has not

been fully explored.

Amino acid modulation of
Acute intra-hippocampal

administration of leucine and chronic administration of branched-chain amino acids
(BCAA: leucine, isoleucine, valine) impair memory in a manner suggested to resemble
Maple syrup urine disease (56, 169).

Intra-cranial injections of glutamine impair

memory formation in the chick but oral administration improves it in rats (55, 86).
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These variable results stem from the diversity of animal models, modes of amino acid
administration and lack of knowledge about the mechanisms involved. Nevertheless,
the role leucine and glutamine play in mTORC1 signaling suggests that their fine
modulation could have significant effects in LTM.
Understanding the individual events upstream and downstream of mTORC1
and their role in LTM is of great importance to elucidate the complex interaction that
takes place in living organisms to form memories. This knowledge is also crucial to
develop specific approaches to treat diseases in which mTORC1 dysregulation causes
neuropsychological impairments.

MTORC1 AND MEMORY DYSFUNCTION

MTORC1 presence throughout the nervous system, together with its ability to
regulate key processes required for cellular growth and proliferation; make this
pathway crucial for preserving neuronal health.

After nervous system trauma,

mTORC1 activity can become highly upregulated (20, 25). Whether this upregulation
of mTORC1 exacerbates or improves cognitive outcome is not well understood (38,
96).

Following spinal cord injury, exercise-induced or ATP-induced mTORC1

activation correlates with increased plasticity and locomotor function recovery (76,
119). Additionally, mTORC1 activation is required for axonal regeneration of adult
retinal ganglion cells and corticospinal neurons after injury (120, 148).

However,

traumatic brain injury (TBI) studies suggest that mTORC1 inhibition with rapamycin
improves functional recovery and decreases posttraumatic epilepsy (44, 60, 147).
Parkinson’s disease, Alzheimer’s disease and stroke have also been associated with
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misregulation of mTORC1. Similarly, findings seem contradictory with some studies
suggesting mTORC1 inhibition could be a strategy against these disorders and others
pointing out that its activation instead would be beneficial for treatment (22, 128). The
disagreements in the literature are not unexpected considering that mTORC1
regulates and balances two opposing processes: protein synthesis and degradation.
Understanding how mTORC1 is finely modulated in normal conditions would aid in the
design of treatments for this disorders.
One disease where the role of mTORC1 is better defined is tuberous sclerosis
complex (TSC). TSC is an autosomal dominant disorder arising from a heterozygous
mutation in either TSC1 or TSC2 (1, 192).

TSC patients develop benign tumors

throughout the body (hamartomas), including the brain, and cognitive decline can
range from moderate to severe.

A graded loss of TSC1 or TSC2, which causes

overactive mTORC1, could be the cause of learning and intellectual disabilities
manifested in TSC patients (205). However, loss of heterozygocity as the mechanism
by which hamartomas form in the brain could also cause behavioral abnormalities (58,
70). Despite the lack of mechanistic detail in our understanding of TSC, it is clear that
mTORC1 dysregulation plays a key role in its pathogenesis. Accordingly, mTORC1
inhibitors are being studied as potential treatments for TSC and everolimus, a
derivative of rapamycin, has been approved by the FDA for the treatment of TSC
associated subependimal giant cell astrocytomas (15, 42, 48).
MTORC1 plays a role in long-term memory formation through its ability to
positively regulate protein synthesis. However, there is a gap in our understanding of
mTORC1 graded modulation and its effects on memory.

For example, strong

mTORC1 inhibition with rapamycin impairs memory formation, but TSC, which
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increases mTORC1 activity, causes cognitive deficits.

These results indicate that

normal memory is modulated by a defined range of mTORC1 activity. Future studies
are needed to fully understand how different upstream mTORC1 regulators affect its
downstream effects in a concerted manner that allows for a balanced activation of
mTORC1 in a timely manner.
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CHAPTER 2

Materials and methods
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ANIMALS

All protocols involving the use of animals were in compliance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals and were
approved by the Institutional Animal Care and Use Committee.

Rats

Male Long-Evans rats (250-280 g) were purchased from Charles River
Laboratories (Wilmington, MA). Animals were housed two per cage with a red plastic
tunnel for enrichment. Rats were kept in a 12 h light/dark cycle, water and fed ad
libitum.

Tsc2+/- and Tsc2flox/flox; CamK2a-Cre mice

Tsc2+/- and Tsc2flox/flox; CamK2a-Cre (Tsc2CKO) mice were obtained from Dr.
Michael J. Gambello’s laboratory. A Tsc2 mouse allele flanked by loxP sites (floxed)
was generated by insertion of loxP sites in introns 1 and 4 of the mouse Tsc2 gene
(Tsc2flox/flox mice) (71). To generate Tsc2+/- animals, Tsc2flox/flox mice were crossed to a
mouse strain containing the Cre recombinase gene driven by a Cytomegalovirus
promoter (CMV-Cre). CMV-Cre mice are a general Cre-deletor strain expressing Cre
in all tissues. The resulting progeny were intercrossed to propagate Tsc2+/- mice.
Tsc2+/+ siblings were used as controls in my experiments and homozygous Tsc2-/mice are embryonic lethal. To generate Tsc2CKO mice, Tsc2flox/flox were crossed to
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Jax mice B6.Cg-Tg (Camk2a-cCre)T29-1Stl/J (Jackson Laboratories, Sacramento,
CA, mouse strain #005359). The resulting progeny were intercrossed to propagate
Tsc2CKO mice which contain a deletion created by Cre-recombinase only in
hippocampus.
Mice were kept in a 12 h light/dark cycle, watered and fed ad libitum. Mating
cages housed 2 females and 1 male and litters were sexed and genotyped at P10. At
P21 litters were separated according to gender and 5 animals housed per cage.

Genotyping: P10 mice were sexed and labeled by a skin punch taken from their ear.
DNA was extracted from ear tissue and prepared for PCR using REDExtract-N-Amp™
Tissue PCR Kit (Sigma-Aldrich, St. Louis, MO). To genotype Tsc2+/- and Tsc2+/+
mice, two forward primers A- 5’ CCTCCTGCATGGAGTTGAGT 3’ and B- 5’
CAGGCATGTCTGGAGTCTTG

3’

and

one

reverse

primer

C-

5’

GCAGCAGGTCTGCAGTGAAT 3’ were designed to detect a 390 bp PCR product
from a wild type allele and a 547 bp PCR product corresponding to a shortened gene
region from where exons 2-4 were excised by Cre (Figure 2.1A and B). A third 434 bp
PCR product was also detected corresponding to the floxed allele (Figure 2.1A, B). A
second PCR was run to confirm the presence of Cre (219 bp band) and a positive
control (Receptor associated protein of the synapse, Rapsn, 590 bp band) in
Tsc2CKO mice (Fig 2.1C).
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Figure 2.1: Genotyping scheme.

A) Schematic showing the Tsc2 murine gene,

located in chromosome 17. The illustration shows the location of inserted loxP sites
as well as the primers used for genotyping. There are 3 viable PCR products. Top,
exons 2-4 knocked-out by Cre recombinase (547 bp). Middle, presence of loxP sites
without excision by Cre (434 bp). Bottom, wild-type allele (390 bp). B) Representative
26

DNA gel showing possible alleles in mouse cohorts.

C) Since Cre expression is

restricted to hippocampal neurons, and ear tissue was used for DNA extraction,
Tsc2CKO animals required a second PCR to confirm the presence of Cre (219 bp).
Rapsn was used as a positive control for amplification (590 bp).

CELL CULTURE

Mouse brain endothelial cells, bEnd.3 stock # CRL2299 were purchased from
American Type Culture Collection (Manassas, VA). bEnd.3 cells were maintained at
less than 60%-80% confluence in DMEM (Delbecco’s modified Eagle’s medium, Life
Technologies) supplemented with 10% fetal bovine serum and penicillin/streptomycin
(5000 U/5000 µg/ml). Cells were seeded in tissue-culture treated dishes at 600-800
cells/cm2 and passed every 3-4. Passage number and culture confluence were noted
for each experiment. Cells used for experimentation were between passages 27-35.
bEnd.3 cells were grown in DMEM supplemented with 10% fetal bovine serum
and penicillin/streptomycin (5000 U/5000 µg/ml). bEnd.3 cells were seeded in tissueculture treated dishes at 2000 cells/cm2. 48 hrs after reaching confluence, cells were
incubated for 2 h with either serum-free DMEM lacking glutamine or DMEM with serum
(Life Technologies, Grand Island, NY). Glutamine (5 mM and 40 mM) (Sigma-Aldrich,
St. Louis, MO) or vehicle was then added to the plates (33, 138). After 30 min, media
was removed, plates quickly washed with 1X PBS and cells lysed in boiling NuPAGE®
LDS sample buffer.

Protein concentrations were determined with a NanoOrange

Protein Quantification Assay (Invitrogen, Carlsbad, CA), using bovine serum albumin
(BSA) as the standard and samples stored at -20C to be used for western blot
experiments.
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SURGICAL PROCEDURES

Closed Head Injury

A single mild closed head injury (mCHI) was delivered to mice essentially as
previously described (80).

Tsc2+/- and Tsc2+/+ control littermates mice were

anesthetized with 5% isofluorane in a 1:1 O2/air mixture then maintained with 2.5%
isofluorane in a 1:1 O2/air via face mask for the remainder of the surgical procedure. A
midline incision was made to expose the skull and anesthesia discontinued.
Immediately after, mice were placed in a foam pad that kept its head level with its
body. A pneumatically driven controlled cortical impact (CCI) device with a metal
impactor tip (5 mm in diameter) was used to deliver a single impact to the skull
(between lambda and bregma over the sagittal suture). The impactor was driven at 55
psi to a depth of 1 mm. Immediately following impact, apnea was monitored. When
breathing returned to normal the scalp was closed with sterile surgical staples.
Animals were monitored for recovery of tail pinch response and righting response
(time it takes the animal to right itself from being placed on its back). Sham animals
received the same treatment but without the impact.

Hippocampal cannulations and infusions

Hippocampal cannulations were performed as previously described (31). Rats
were anesthetized with 4% isoflurane in a 2:1 N2O/O2 mixture and then maintained
with 2% isoflurane/2:1 N2O/O2 mixture via face mask. Bilateral guide cannulas aimed
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at the dorsal hippocampus (anteroposterior, -3.3 mm, lateral, ±2.0 mm from bregma;
ventral, -2.0 mm from the dura), were implanted. Then rats were allowed to recover in
their home cages for 10 days. Injection cannulas extended 1.75 mm beyond the tips
of the guides, yielding a total depth of 3.75 mm below the dura. Sterile L-glutamine
(194 mM) and L-leucine (137 mM) were prepared in saline before infusion.

All

injections (1.3-1.5 µl/hippocampus of either drug or saline) were performed in freely
moving animals at a rate of 0.2 µl/min via dual syringe infusion pump (Stoelting, Wood
Dale, IL).

Cannula placement

After completion of all behavioral experiments involving animals with implanted
cannulas, animals were killed and brains quickly removed for histological assessment.
Brains were cut into 2 mm coronal sections while being bathed in ice-cold artificial
cerebrospinal fluid (aCSF). The coronal section containing the infusion site was dropfixed in a 4% paraformaldehyde and 15% picric acid in phosphate buffer saline
solution (PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4) overnight. Brains were then cryoprotected in a 30% sucrose solution in PBS. Coronal
brain sections (40µm) were collected using a cryo-stat. Serial section around the
infusion site were mounted on gelatin-coated glass slides and partially dehydrated in
50% ethanol. Sections were then stained with cresyl violet acetate (Sigma-Aldrich, St.
Louis, MO) and completely dehydrated in 100% EtOH followed by 3 xylene
incubations.

Lastly, sections were cover slipped in Permount (Fisher Scientific,
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Pittsburgh, PA) and let dried over-night. Images were taken using a Zeiss Axiovert
S100 microscope and a MicroFire camera (Optronics, Goleta, CA).

BEHAVIORAL TASKS

All behavioral experiments were performed by an experimenter who was kept
blind to the treatment schedule.

Beam balance task

To assess vestibulomotor and motor functions of Tsc2 +/- sham and injured mice
the beam balance task was performed (4, 202). On the day after injury, animals were
given 3 trials of 1 min each on the beam. Animals were placed at the farthest end of a
metal beam (0.5 cm wide) and time balancing was recorded. If 60 seconds passed
without the mouse falling, the trial was terminated. At the end of each day, data from
each animal was averaged and group averages compared.

When all groups

performed similar to sham controls, testing was ended.

Foot fault task

A second task used to assess vestibulomotor and motor functions of Tsc2+/sham and injured mice was the foot fault task (4, 202). For this task, a mouse is
placed on a wire grid with an opening size 1 X 1 cm, and left to walk until the
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experimenter counted 50 steps. Foot faults were recorded when any of the front paws
passed below the plane of observation through a gap in the grid. Each animal was
given three trials per day until all groups performed as well as sham controls.

Abbreviated version of the Morris Water Maze (MWM)

Cannulated animals were trained in an abbreviated form of the hidden platform
version of the Morris water maze task (61, 135, 170). Animals were trained to criterion
(three consecutive trials with a platform latency of <10 s). Each trial started by placing
the animal in one of four randomly chosen locations, facing the wall of the tank.
Animals were allowed to search for the platform for 60 s. If an animal failed to find the
platform, it was placed there by the experimenter. Animals were allowed to remain on
the platform for a period of 30 s before being returned to a warming cage between
trials. The inter-trial interval was 4 minutes. Once criterion was reached, animals
were immediately infused bilaterally with the corresponding amino acid solution or
vehicle. At 48 h after training the animals were tested for memory retention by a probe
trial in which the hidden platform was removed from the maze and the animals were
allowed to search for a period of 60 s. Animals were monitored by a video camera
linked to tracking software (Ethovision, Noldus). Data collected during the probe trial
was divided into respective treatment groups and analyzed for latency to reach the
platform location, number of times the area of the platform was crossed, swim velocity
and latency, dwell time and number of crossings to concentric rings of decreasing
diameter around the platform area. After the probe trial was complete, the platform
was placed back into the swimming tank with a visual flag on top. Animals were given
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3 trials in which they were allowed to find the marked platform placed in different
places each trial.

Fear context discrimination

Fear context discrimination was done by pre-exposing animals for 10 min to two
contexts without shock. These contexts shared certain features (background noise,
horizontal grid floor, animal handling to and from the room) but differed in others
(differently spaced grids, distal cues, floor color, space shape and scent). Animals
were given 2 trials a day, one in each of the two chambers. Half of the animals from
each group were trained in the morning in the shock chamber were they stayed for 3
min and a 2 s, 0.75 mA shock given at 148 s. Then, in the afternoon, they were
placed in the safe chamber for 3 min and no shock was given. The complement half
of each experimental group experienced the same treatment but experienced the
shock chamber in the afternoon instead. The following day discrimination between the
two contexts was assessed by monitoring freezing behavior, in 2 sec intervals for 3
min, in each chamber. Contextual discrimination was tested daily; data was compiled
and analyzed to determine if contextual discrimination was learned. If learning did not
happen, then training continued for an extra day until discrimination was achieved
(47).
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Delayed fear conditioning

Animals were placed in the training chamber and were allowed to explore for
120 s. Then a 30 s tone was presented and during the last two seconds, the animals
were given a 0.8 mA foot shock through the grid floor (US). Animals were given three
successive training trials followed by a one-minute rest period. Animals were then
returned to their home cages until retention testing. Memory for the context, the tone
and a novel but similar context was independently tested 48 hours later by measuring
percent freezing. Freezing was defined as the complete lack of movement except that
required for breathing. To test for contextual memory, animals were placed back in
the training chamber for 3 minutes and freezing behavior was measured at 3-second
intervals. To test for fear generalization, animals were placed in a novel context that
shared certain features with the training context (horizontal grid floor, background
noise, animal handling to and from the room) while differing in others (differently
spaced grids, scent, distal cues, floor shape and color) for 3 minutes and freezing
behavior was measured at 3-second intervals. To test for hippocampal-independent
tone memory, animals were placed in a completely different and novel context (plastic
floor and walls, different lighting and patterns on the walls) and freezing behavior was
tested for 3 minutes during which the tone was being played. Freezing behavior was
monitored and recorded both before and during training (47, 153, 162, 200).
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WESTERN BLOTS

Antibodies
The following primary antibodies were purchased from Cell Signaling
Technology (CST) (Danvers, MA) and dilutions used as follow:


Phosphorylated S6 (Serine 240/244) CST Cat. #5364, 1:2000



Total S6 CST Cat. #2217, 1:2000



Phosphorylated S6 Kinase (Threonine 389) CST Cat. #9205, 1:1000



Total S6 Kinase CST Cat. #9202, 1:1000



Phosphorylated Tuberin (Threonine 1462) CST Cat. #3611, 1:1000



Total Tuberin CST Cat. #3612, 1:1000



Phosphorylated ULK1 (Serine 757) CST Cat. #6888, 1:1000



Total ULK11 CST Cat. #8054, 1:1000



Phosphorylated AMPK (Threonine 172) CST Cat. #2531 1:500



Phosphorylated p44/42 MAPK (Erk1/2) (Threonine 202 / Tyrosine 204)
CST Cat. #9101, 1:1000

The following primary antibodies were purchased from Sigma-Aldrich (St.
Louis, MO) (SIG) and dilutions used as follow:


Total Beclin-1 SIG Cat. #B6186, 1:1000



Total β-actin SIG Cat. #A2228, 1:100000

To determine how many µg of tissue sample to load for each antibody to fall
within its linear range of detection, an initial western blot was run with increasing
amounts of protein, and each antibody tested at the concentrations indicated by the
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manufacturer. When necessary, antibody concentrations were adjusted to allow for
the proper amount of sample to be loaded into wells.
Alkaline-phosphatase conjugated goat anti-rabbit IgG (AP1000) and alkalinephosphatase conjugated goat anti-mouse IgG (AP2000) secondary antibodies were
purchased from Vector Laboratories (Burlingame, CA). These antibodies were used at
a 1:20000 dilution.

Sample preparation

Animals were infused with an amino acid solution into one hippocampus and an
equal volume of vehicle into the contralateral hippocampus of the same animal. At the
indicated time points after infusion, animals were killed and hippocampal punches (2
mm in diameter) surrounding the infusion site were taken while brains were
submerged in ice-cold artificial CSF containing phosphatase inhibitors (2 mM NaF, 2
mM Na2MoO4, and 1 mM Na3VO4).

Tissues were disrupted by 2 second, 20%

amplitude sonication pulses (Vibra Cell, Ultrasonic processor 130 watt, 20 Khz)
(Sonics, Newtown, CT) in buffer (10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM EDTA, 0.5
DTT, 0.1 µM okadaic acid and 1 mM Na3VO4, 1 mM PMSF and 10 µg/ml leupeptin).
After NuPAGE® LDS sample buffer was added (Invitrogen® by Life TechnologiesTM)
was added, the protein concentration was determined by NanoOrange Protein
Quantification Assay (Invitrogen, Carlsbad, CA) using bovine serum albumin (BSA) as
the standard.
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Western blot

Samples were boiled in NuPAGE® LDS sample buffer and resolved on
NuPAGE® Bis-Tris mini gels (Novex® by Life TechnologiesTM). Proteins were then
transferred to Immobilon-P (Millipore, Bedfore, MA) membranes and blocked for 30
min in 5% BSA in TBST. Primary antibodies were diluted in 2% BSA in TBST as
indicated in section 2.5.1 and incubated overnight at 4ºC. Membranes were then
washed 5 times in TBST and incubated at room temperature with alkaline
phosphatase-conjugated secondary antibodies at concentrations indicated in section
2.5.1 for 1 hour. Membranes were washed again and immunoreactivity was detected
using the CDP-Star chemiluminescence system (New England Biolabs, Beverly, MA)
and visualized on Kodak XAR5 film (Rochester, NY).

Quantification of western blot bands

Luminescent membranes were exposed to film with varying exposure times to
ensure some blots fell within the linear range. Blots that were too dark were not used
for analysis. Exposed film were scanned and analyzed using Image processing and
analyzing in java (ImageJ) (171). Using the rectangular selection tool, samples were
selected horizontally, then vertically (same rectangle size for each sample).

The

ImageJ program measured arbitrary units for each sample and plotted the results.
The area under each curve was calculated and both horizontal and vertical measures
averaged. When samples were selected, 1 cm to each side (horizontal measure) or 1
cm above and below (vertical measure) each band was included and used to remove
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background optical density produced by the film itself.
normalized against β-actin.

All antibodies tested were

Western blot data were compiled from at least 3

independent animals or cell culture experiments and samples were run at least twice
to confirm results.

IMMUNOHISTOCHEMISTRY

Antibodies
The following primary antibodies were diluted and used as follow:


Phosphorylated S6 (Serine 240/244) CST Cat. #5364, 1:2000



Anti NeuN antibody was purchased from Millipore (Billerica, MA) (Cat.
#MAB377, 1:1000).



Alexa Fluor® 568 Goat Anti-Rabbit IgG (Cat.

#A11011, 1:500) was

purchased from Invitrogen® by Life TechnologiesTM (Grand Island, NY).


Alexa

Fluor®

488

Goat

Anti-Mouse

IgG

(Invitrogen®

by

Life

TechnologiesTM Cat. #A11001, 1:500)

Preparation of tissue sections

Tsc2CKO mice at 5 weeks of age were given 2 daily doses of either 3 g/kg
glutamine or saline via gavage for 2 weeks. 1 h after the last dose, animals were
decapitated, and brains immediately removed. Samples from untreated age-matched
control littermates were also collected. Brains were cut in coronal sections of 2 mm
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while being bathed in ice-cold artificial CSF containing phosphatase inhibitors (2 mM
NaF, 2 mM Na2MoO4, and 1 mM Na3VO4). Coronal sections were then drop-fixed in a
4% paraformaldehyde and 15% picric acid in phosphate buffer saline solution (PBS)
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4) over-night. Brains were
then cryoprotected in a 30% sucrose solution in PBS. Coronal brain sections (40 µm)
were collected using a cryo-stat and stored in protective solution (3.4 M C3H8O3, 5.4 M
C2H6O2, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4).

Immunohistochemistry

Brain sections were washed 3 times in PBS solution and then incubated with
primary antibodies (pS6 and NeuN) overnight at 4ºC in a 0.25% Triton X-100 PBS
solution (PBST) with 2% BSA and 2.5% normal goat serum. Brain sections were then
extensively washed in PBST and incubated for 1 h in species-specific secondary
antibodies conjugated to Alexa-fluors. Finally, sections were mounted on glass slides
and cover slipped using FluoromountG (SouthernBiotech, Birmingham, AL).

Immunofluorescence quantification

Images of immunofluorescence were taken using a Zeiss Axiovert S100
microscope and a MicroFire camera (Optronics, Goleta, CA). The parameters used
for image capturing were determined using control littermate samples to minimize
background and optimize the signal. These parameters were kept constant across all
groups. Three non-overlapping regions in the dentate gyrus of the hippocampus and
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two sections from each animal (n=5/group) were used for quantification. Fluorescence
intensities were measured using Photoshop software (Adobe, San Jose, CA).
Luminosity was measured in CA1, CA3 and 3 areas of the dentate gyrus using a
rectangular selection tool with equal size for every sample. Relative fluorescence
intensity units (FIU) were averaged for each section then 2 sections averaged for each
animal.

STATISTICS

In all experiments, data collected from the same animal with one or more
factors, was subjected to repeated measures (RM) ANOVA. Data comparing only one
factor between groups, such as probe trial data analysis and western blot data, were
subjected to a two-tailed Student’s t-test for unpaired (behavioral data) or paired
variables (Western blot data and contextual discrimination data).

Data comparing

more than 2 groups were subjected to One-way ANOVA. The analysis of survival was
performed using the Kaplan–Meier method. Comparisons between average survival
times were carried out using the log-rank test. Data were considered significant at
p<0.05.
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CHAPTER 3

Over-activation of mTORC1 exacerbates
cognitive impairment after a mild closed head injury
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INTRODUCTION

Mild traumatic brain injury (mTBI), caused by a kinetic blow to the head,
accounts for 75% of the 1.7 million TBIs that occur each year (2). People who have
suffered more than one mTBI (contact sports athletes and brain injured soldiers) are
more likely to develop early onset Alzheimer’s disease, chronic traumatic
encephalopathy and dementias than the uninjured. This link, between early onset
neurodegenerative disorders and mTBI, has recently created great interest in this field
of research (32, 35, 144). Early symptoms reported include headaches, unsteadiness,
vomiting, sleeping problems, impaired memory, attention deficits and inability problem
solving (117, 131, 155). These symptoms commonly last between days and weeks
post-injury and most mTBI patients often recover completely.
Despite the fact that many mTBI patients experience complete recovery, there
can be long-lasting consequences for some patients both at the functional and
structural levels. At the functional level, persistent cognitive impairments and risk for
the severe consequences of a second injury (second impact syndrome), may happen
(8, 10, 107). Evidence suggests that a history of mTBI can cause long-term structural
changes in the frontal, parietal and temporal brain cortices as well as decreased
hippocampal volume and reduced neuronal activity (132, 189).

Whether these

changes contribute to the chronic nature of the neurobehavioral dysfunctions seen in
mTBI patients or not is still unclear. Secondary injury events caused by trauma, like
delayed metabolic and molecular disruptions, may be responsible for the increased in
brain vulnerability. Many studies have focused their research on these secondary
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injury mechanisms because their late start and evolution over hours to months present
a potential window for treatment (121).
One example of a secondary mechanism which may be a potential therapeutic
target is autophagy, the main mechanism for bulk degradation of dysfunctional
organelles. This process increases after injury and remains elevated for days (24,
110, 118, 209).

Immediately after injury, autophagy may have beneficial effects

including clearing up cellular debris and working in concert with apoptotic processes to
discard dysfunctional cells (209).

However, chronic elevation of these processes

could be responsible for excessive loss of neurons in surrounding and distant regions
from the injury site.

Indeed, several studies have demonstrated that autophagy

inhibition is correlated with decreased cellular damage and improved behavioral and
cognitive outcome after TBI (125, 199). An opposite approach to treat TBI secondary
injury has been to increase neuronal repair and plasticity.

For example, vascular

endothelial growth factor administration after TBI promotes behavioral recovery
possibly due to its role in activation of neurogenesis and angiogenesis (114, 185, 204).
Application of neurotrophic factors has also been associated with improved outcome
correlated with increased neurite outgrowth, synaptogenesis and neuronal survival
(172).

Intriguingly, autophagy and neuroplasticity are regulated by a common

signaling pathway: the mechanistic Target of Rapamycin Complex 1 (mTORC1)
pathway.
MTORC1 acts as a cellular sensor integrating growth factors, mitogens,
hormones, and ATP availability to regulate cell growth. As there are many injuryrelated alterations in growth factor and cellular energy levels following injury, mTORC1
is a pathway of theoretical interest to the injury literature. Most upstream modulators
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of mTORC1 communicate through the tuberous sclerosis complex (TSC1/2), which
contains TSC2, a GTPase activating protein for Ras homologue enriched in brain
(Rheb).

When TSC2 is active, it inhibits Rheb and its subsequent stimulation of

mTORC1 activity (36, 37, 37, 53, 81, 184, 208). Thus, abnormal inhibition of TSC—as
occurs when Tsc2 is mutated—causes overactivation of mTORC1 (28, 71). Active
mTORC1 phosphorylates and activates S6K and 4E-BP1 to promote mRNA
translation initiation (68, 126). Consequently, deficient neuronal plasticity events after
injury (like impaired long-term potentiation and decreased synaptic density), may be
returned to normal by increasing mTORC1 activity (26). Furthermore, active mTORC1
also phosphorylates ULK1 to inhibit autophagy initiation.

In this case, increasing

mTORC1 would target autophagy which could be beneficial or detrimental for TBI
outcome depending on duration of activation (52, 73, 93, 176).
There has been investigation of mTORC1 activation following injury, but no
conclusive results as to the activation state or its impact upon outcome. One issue
with the current literature is that not enough emphasis has been placed on
investigating mTORC1 activity in a temporal manner.

It has been shown that

mTORC1 activity is increased from 30 min to 24 hours after TBI (20). To test whether
this acute increase in mTORC1 activity is beneficial or detrimental to TBI outcome,
Erlich et al. treated injured mice with Rapamycin, an mTORC1 specific inhibitor, 4 hrs
after injury.

Surprisingly, they found that treated mice had improved neuro-motor

functions compared to the vehicle group (44). However, other work has shown that
rapamycin treatment alone was unable to improve cognitive outcome unless coinfused with an Akt inhibitor (147). Contrary to these findings, chronic elevated levels
of mTORC1 have been shown to be required for axonal regeneration of injured
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peripheral nerves (3). Supporting the view that high mTORC1 activity improves TBI
outcome, increased synapse and axonal recovery growth after TBI was observed
following 14 days of treatment with the drug Simvastatin, which increased
PI3K/Akt/mTORC1 signaling (204). These results suggest that this pathway could be
a potential therapeutic option for TBI patients but it remains unclear whether inhibition
or activation of mTORC1 would improve outcome.
My hypothesis is that if elevated mTORC1 activity is detrimental for TBI
outcome, then TSC2 heterozygous knock-out mice (Tsc2+/KO) will show poor outcome
after brain injury compared to control littermates (Tsc2+/+). To test this hypothesis I
completed the following specific aims:
I.

Genetic rodent models with inactivation of Tsc2 show variable learning and
memory deficits (41, 195). It is not clear whether a graded inactivation of
TSC1/2 (caused by haploinsuficiency) or subsequent loss of heterozygosity
is the mechanism behind cognitive deficits seen in Tuberous Sclerosis
Complex (TSC) patients (28).

I therefore sought to assess the brain

expression levels of Tsc2 and downstream target of mTORC1 (phospho-S6)
and characterize learning and memory performance in our Tsc2+/KO mice.
II.

MTORC1 activity increases following brain injury and its inhibition with
rapamycin improves outcome (20, 44). Therefore, I anticipated that Tsc2+/KO
mice, which have increased mTORC1 activity, would have an exacerbated
and acute impairment of memory and increased mTORC1 activity after a
mild closed head injury (mCHI). I investigated this possibility by delivering a
mild CHI to Tsc2+/KO and Tsc2+/+ mice and testing phospho-S6 levels 30
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minutes after injury and learning and memory performance one week
following the insult.
III.

It is still unclear if mTORC1 activity could be beneficial or detrimental in the
chronic phases after brain injury. Some studies suggest that mTORC1 role
in cellular growth and plasticity would be beneficial, while others argue
against it (38, 96). To test whether overactivation of mTORC1 improves TBI
outcome, I assessed phospho-S6 levels seven weeks after mCHI and tested
learning and memory performance five weeks following injury in Tsc2+/KO
mice.

MTORC1 ACTIVITY IS ELEVATED IN TSC2+/KO MICE BUT LEARNING AND
MEMORY PERFORMANCE IS COMPARABLE TO TSC2+/+ MICE

mTORC1 activity is elevated in Tsc2+/KO mice

Tsc2+/KO mice were generated in Dr. Gambello’s laboratory and have been
previously described. These animals show decreased Tsc2 protein levels and elevated
phospho-S6 (71). To reproduce these results, I used cortex and hippocampal tissue
from Tsc2+/KO and Tsc2+/+ and compared protein levels of tuberin, phospho-S6 and
total S6 by western blot. As expected, a mild decrease in tuberin levels of Tsc2+/KO
brains was observed (Fig 3.1A). Tuberin binds to hamartin to form the TSC complex
which acts as a negative regulator of mTORC1 activity. The mutation is expected to
decrease the amount of active TSC complex, leading to decreased inhibition of
mTORC1 and increased phosphorylation of its downstream targets. My results show
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that levels of phospho-S6 are significantly higher in Tsc2+/KO than Tsc2+/+ mice while
its total levels remain unchanged (Fig 3.1B and C).

Figure 3.1: Tsc2 is reduced while pS6 is elevated in Tsc2+/KO mice. Tsc2+/KO mice
(n=5) and control littermates (n=5) of 2 month of age were decapitated and brain
samples collected for western blot analysis. A) Tsc2+/KO mice have significantly lower
levels of tuberin than control littermates (Tsc2+/+) in cortex (left, p=0.037) and
hippocampus (right, p=0.019). B) Tsc2+/KO mice have significantly higher levels of
phosphorylated-S6 than Tsc2+/+ in cortex (left, p=0.039) and hippocampus (right,
p=0.028). C) There is no significant difference in total levels of S6 between the two
groups in cortex (left, p=0.5) and hippocampus (right, p=0.8). Data are represented as
the mean ± s.e.m; statistical analysis done by 2-tailed, unpaired student’s t-test;
*p≤0.05.
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Tsc2+/KO mice have no motor or cognitive deficits

Brain injury can cause motor and vestibulomotor deficits which can be detected
using the foot fault and beam balance tasks, respectively. To ensure that any effects
following TBI were specific to the injury and not due to a baseline difference in motor
and cognitive performance, I tested animals in the beam balance and foot fault tasks.
When Tsc2+/KO mice are compared to Tsc2+/+ control litter mates, there is no difference
in time balancing on the metal beam or foot faults while walking on a metal grid (Fig
3.2).
Upon confirmation that there were no pre-existing deficits in motor performance,
I then trained and tested Tsc+/KO and Tsc2+/+ mice in an abbreviated version of the
Morris water maze to investigate their abilities to form hippocampal-dependent
memories. Animals were given 10 consecutive trials (4 min inter-trail-interval) to find a
hidden platform in the water maze. There was no difference in learning between
Tsc2+/KO and Tsc2+/+ groups (Fig 3.3A). When tested for long-term memory 24 h after
training, there was no significant difference in latency to the original platform location
or number of crosses through the platform area (Fig 3.3A and B). This suggests that
Tsc2+/KO mice are able to form normal long-term spatial memories.

48

Figure 3.2: Motor skills are not affected in Tsc2+/KO mice. Tsc2+/KO mice (n=10) and
Tsc2+/+ (n=9) of 2 to 4 month of age were tested for motor ability. A) There was no
difference between the groups in the paw placement task, p=0.8. B) There was no
difference between the groups in the beam balance task, p=0.2.

Data represent

means ± s.e.m.
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Figure 3.3: Tsc2+/KO mice have no deficit in the Morris Water Maze task. Tsc2+/KO
mice (n=10) and Tsc2+/+ (n=9) were trained in a 1-day Morris Water Maze protocol. A)
There was no difference during learning between the groups, (2-way repeated
measures of ANOVA with group and training trial as between subject factors:
F(4,68)=0.393, p=0.8). There was no significant difference between the groups in a
probe trial given 24 hrs later, latency is shown (2- tailed, unpaired student’s t-test;
p=0.5). B) There was no difference between the groups in the number of crossings
during the probe trial (2- tailed, unpaired student’s t-test; p=0.25). C) There was no
difference between the groups in the latency to a visual platform (2- tailed, unpaired
student’s t-test; p=0.8).

D) There was no difference between the groups in swim

velocity during the probe trial (2- tailed, unpaired student’s t-test; p=0.3).

Data

represent means ± s.e.m.
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To further confirm that Tsc2+/KO mice have no deficits making hippocampaldependent memories, mice were trained in a fear context discrimination paradigm.
Animals were initially pre-exposed to the shock chamber and to a modified chamber
resembling the shock cage but differing in wall cues, scent, floor grid spacing and
shape (safe cage). Half of the animals from each group were given a morning trial in
the shock cage (3 min, 2 s 0.75 mA shock given at 148 s) and an afternoon trial in the
safe cage (3 min, no shock). The other half of the animals received the same training
but in reverse order. To assess fear memory retention, animals were placed in each
cage 24 h later and freezing behavior monitored. My results show that both groups
froze for a significantly longer period of time in the shock cage than in the safe cage
(Fig 3.4). This result indicates that Tsc2+/KO mice were able to remember the contextshock relationship as well as control litter mates, and supports the idea that Tsc2+/KO
mice present no pre-existing hippocampal-dependent memory deficits.

Figure 3.4: Tsc2+/KO mice have no deficit in a fear context discrimination task.
Tsc2+/KO mice (n=10) and Tsc2+/+ (n=9) were trained in a context discrimination task
for one day and tested for memory 24 hrs later, % freezing is shown for baseline
conditions. A) Control mice froze significantly less time in the safe cage than in the
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shock case, indicating they could discriminate between them, p=0.024. B) Tsc2+/KO
mice froze significantly less time in the safe cage than in the shock case, indicating
they could also discriminate between the two cages, p=0.004. Data represent means
± s.e.m., statistical analysis done by 2-tailed, unpaired student’s t-test, *p<0.05,
**p<0.01.

MTORC1 ACTIVITY IS FURTHER ELEVATED IN TSC2+/KO MICE AFTER CLOSED
HEAD INJURY

As shown in the previous section, Tsc2+/KO mice have constitutively elevated
mTORC1 activity, but have no learning and memory deficits in the Morris water maze
or context discrimination tasks.
To test if a brain injury differentially activates mTORC1 in Tsc2 +/KO and Tsc2+/+
littermate mice, a mild closed head injury (CHI) was delivered to animals of both
groups. Figure 3.5 shows that both groups had comparable apnea time, response
time to a tail pinch and righting responses. This indicates that the severity of the
concussion was comparable in both groups. Brains were dissected 30 min after injury
and hippocampus (HIPP) and cortex (CTX) tissue was collected for western blot
analysis.
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Figure 3.5: There is no difference in apnea, Tail pinch and Righting response between
Tsc2+/KO and control mice after closed head injury. Tsc2+/KO mice (n=5) and control
littermates (n=6) of 2-4 months of age were injured with a pneumatically driven
controlled cortical impact device and the following test performed immediately after the
impact. A) There was no difference in apnea between the two groups, p=0.7 B) There
was no difference in tail pinch response between the two groups, p=0.3 C) There was
no difference in righting response between the two groups, p=0.2.

Data are

represented as the mean ± SEM; statistical analysis done by 2-tailed, unpaired
student’s t-test.

To test whether or not mTORC1 activity was differentially upregulated in
Tsc2+/KO and Tsc2+/+ mice, western blots were performed using phospho-S6, a
sensitive downstream target of mTORC1. My results show that phospho-S6 levels did
not change when injured Tsc2+/+ are compared to sham controls (Fig 3.6A). However,
when Tsc2+/KO are injured, higher levels of phospho-S6, but not its total levels, are
observed when compared to their sham group (Fig 3.6B and C).
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(On previous page)
Figure 3.6: Phosphorylated S6 levels are elevated in Tsc2+/KO mouse brains 30
minutes after CHI. Tsc2+/KO mice (n=5) and Tsc2+/+ (n=6) of 2-4 months of age were
injured with a pneumatically driven controlled cortical impact device and brain tissue
dissected 30 min after the impact. A) Top, representative western blots. Bottom left,
pS6 levels do not change after CHI in control mice in cortex (p=0.4) and hippocampus
(p=0.6) when compared to sham control mice (n=6). Bottom right, total S6 levels do
not change after CHI in control mice when compared to sham group (CTX p=0.4, HIPP
p=0.3). B) Top, representative western blots. Bottom left, pS6 levels are significantly
higher than sham control mice (n=6) in Tsc2+/KO mouse cortex (p=0.0009) and
hippocampus (p=0.0003). Bottom right, total S6 levels do not change after CHI in
Tsc2+/KO mice when compared to control sham (CTX p=0.4, HIPP p=0.4).

Data

represent means ± s.e.m., statistical analysis done by 2-tailed, unpaired student’s ttest, ***p<0.001.

MTORC1 has been shown to regulate autophagy by phosphorylating, and
inhibiting ULK1.

To test the possibility that injury-associated increased mTORC1

activity also affected this target, brain samples were tested by western blot using a
phospho-ULK1 antibody. Figure 3.7 shows that injured control Tsc2+/+ mice do not
show increased phospho-ULK1 levels when compared to sham controls (Fig 3.7A).
On the other hand, injured Tsc2+/KO mice show elevated phospho-ULK1 levels when
compared to Tsc2+/KO sham, while its total levels remain unchanged (Fig 3.7B). This
result complements the previous finding that mTORC1 activity is elevated in injured
Tsc2+/KO but not injured Tsc2+/+ and suggest that mTORC1 activation following TBI
affects both autophagy and protein synthesis.
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(On previous page)
Figure 3.7: Phosphorylated ULK1 levels are elevated in Tsc2+/KO mice 30 minutes
after CHI. Tsc2+/KO mice (n=5) and Tsc2+/+ (n=6) of 2-4 months of age were injured
with a pneumatically driven controlled cortical impact device and brain tissue dissected
30 min after the impact. A) Top, representative western blots. Bottom left, pULK1
levels do not change after CHI in control mice in cortex (p=0.7) and hippocampus
(p=0.9) when compared to a sham group (n=6). Bottom right, total ULK1 levels do not
change after CHI in control mice when compared to a sham group (CTX p=0.7, HIPP
p=0.7).

B) Top, representative western blots.

Bottom left, pULK1 levels are

significantly higher than sham control mice (n=6) in Tsc2+/KO mouse cortex (p=0.01)
and hippocampus (p=0.038). Bottom right, total ULK1 levels do not change after CHI
in Tsc2+/KO mice when compared to control sham (CTX p=0.9, HIPP p=0.6). Data
represent means ± s.e.m., statistical analysis done by 2-tailed, unpaired student’s ttest, *p<0.05.

However, there is also a possibility that Tsc2+/+ mice do not show elevated
levels of mTORC1 activity because the concussion was too mild to create any deficits.
Therefore, the levels of Beclin-1 were also tested in these samples. Beclin-1 is a
protein involved in autophagy activation and its total levels have been shown to be
elevated after brain injury. My results show a significant increase in the total levels of
Beclin-1 in both injured groups (Fig 3.8A and B). These results support the idea that
brain injury differentially affects mTORC1 activity in Tsc2+/KO mice than control
littermates. In summary, upon a mild closed head injury, a noticeable increase in the
phosphorylation levels of mTORC1 downstream target S6 is only observed when Tsc2
levels are decreased (haploinsuficiency). Furthermore, phosphorylation of a second
mTORC1 target, ULK1, necessary to regulate autophagy, is also increased only in
Tsc2+/KO injured animals. These results suggest that abnormal mTORC1 activity due
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to partial lack of Tsc2 regulation decreases the internal threshold to elevate mTORC1
activity after injury.

Figure 3.8: Beclin-1 levels are elevated 30 minutes after CHI in the cortex of Tsc2+/KO
and Tsc2+/+ mice. Tsc2+/KO mice (n=5) and control littermates (n=6) of 2-4 months of
age were injured with a pneumatically driven controlled cortical impact device and
brain tissue dissected 30 min after the impact. A) Representative western blots. B)
Beclin-1 levels are elevated 30 min after CHI in both Tsc2+/+ (p=0.004) and TSC2+/KO
mice (p=0.0002) when compared to a respective sham group. Data represent means
± s.e.m., statistical analysis done by 2-tailed, unpaired student’s t-test, **p<0.01,
***p<0.001.
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COGNITIVE IMPAIRMENT IS EXACERBATED IN TSC2+/KO MICE AFTER CLOSED
HEAD INJURY

I have shown in the previous section that a mild closed head injury increases
levels of phosphorylated S6 and ULK1, two downstream targets of mTORC1. To test
whether or not acute activation of mTORC1 signaling is detrimental to cognitive
outcome after TBI, Tsc2+/KO and control littermates were injured and their memory
forming ability tested in the Morris water maze and context discrimination tasks.
Figure 3.9 shows the timeline of experiments performed following delivery of a mild
closed head injury.

Figure 3.9: Time line of experiments. Tsc2+/KO mice (n=9) and Tsc2+/+ (n=10) of 2-4
months of age received a closed head injury with a pneumatically driven controlled
cortical impact device. Immediately after the impact, acute neurological tests (apnea,
tail pinch response and righting response) were performed. On the first day after the
injury, animals were tested on 2 motor skills tasks: paw placement and beam balance.
During the first week after CHI, animals were trained and tested in a 1-day protocol of
the Morris water maze. During the second week after CHI, animals were trained and
tested in a fear context discrimination task.
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Immediately after the injury, animals were tested for apnea, tail pinch and
righting response times. There was no difference in any of these tests between the
two injured groups indicating that severity of the injury was equal in both groups (Fig
3.10A, B and C). Figure 3.10D shows that both injured groups performed the foot fault
tasks in a comparable manner to sham animals, suggesting no deficits in this test.
Figure 3.10E shows that both injured groups were similarly impaired in the foot fault
tasks and took them the same time to recover to sham standards.

This again

suggests that the injury level was similar in both groups and affected their ability to
recover in a similar manner.
One week after injury, animals were trained to find a hidden platform in the
Morris water maze. Mice were given 10 consecutive trials (4 min ITI) and returned to
their home cages. Figure 3.11A shows that both injured groups learned the task. To
test for memory of the platform location, animals were given a probe test 24 h after the
last training trial.

Figure 3.11A and B show that Tsc2+/KO mice spent more time

searching without finding the platform location (Tsc2+/+ 29.1 ± 8.1 latency; Tsc2+/KO
50.31 ± 5.2, p=0.046) and crossed the platform area less times than Tsc2 +/+ mice
(Tsc2+/+ 1.4 ± 0.4 crossings; Tsc2+/KO 0.33 ± 0.1, p=0.039). These results suggest that
long-term memory of the platform location was impaired in Tsc2 +/KO injured mice when
compared to injured control littermates. The results cannot be attributed to visual
acuity problems or swimming deficits since there was no difference between the
groups in latency to find a visible platform (Fig 3.11C) or swim velocity (Fig 3.11D).
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Figure 3.10: There is no difference between Tsc2+/KO mice and control littermates in
acute neurological tests and motor skills after a mCHI. A sham group (n=8) is shown
for reference on each panel. A) There was no significant difference in apnea between
the two groups, 2-tailed, unpaired student’s t-test p=0.8. B) There was no significant
difference in tail pinch response between the two groups, 2-tailed, unpaired student’s
t-test p=0.2. C) There was no significant difference in righting response between the
two groups, 2-tailed, unpaired student’s t-test p=0.4.

D) There was no significant

difference in the paw placement task (2-way repeated measures of ANOVA with group
and training day as between subject factors: F(2,32)=1.044, p=0.36. E) There was no
significant difference in the beam balance task between the groups, (2-way repeated
measures of ANOVA with group and training day as between subject factors:
F(2,34)=0.329, p=0.7). Data are represented as the mean ± s.e.m.
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Figure 3.11: Tsc2+/KO mice exhibit impaired memory in the MWM task after a mCHI. A
sham group (n=8) is shown for reference on each panel. A) There was no difference
during learning between the groups, (2-way repeated measures of ANOVA with group
and training trial as between subject factors: F(4,68)=1.021, p=0.4).

A significant

difference in a probe trial given 24 hrs later between the groups was found, latency is
shown (2- tailed, unpaired student’s t-test; p=0.046). B) There was also a significant
difference in the number of crossings during the probe trial (2- tailed, unpaired
student’s t-test; p=0.039). C) There was no difference between the groups in the
latency to a visual platform (2- tailed, unpaired student’s t-test; p=0.9). D) There was
no difference between the groups in swim velocity during the probe trial (2- tailed,
unpaired student’s t-test; p=0.9). Data represent means ± s.e.m., *p<0.05.

To confirm that injured Tsc2+/KO mice have poorer cognitive recovery than
Tsc2+/+ mice, animals were trained in a fear context discrimination task as described in
section 3.2. My results show that, as expected, sham animals are able to learn the
task after only one training trial (Fig 3.12A). Injured Tsc2+/+ mice learn the task a day
slower than sham animals (Fig 3.12B) and injured Tsc2 +/KO mice required 3 trials to
learn the task (Fig 3.12C). These results suggest that Tsc2+/KO mice need an extra
amount of training to distinguish between the shock and safe cages.
In summary, increased mTORC1 activity, due to a Tsc2 mutation, impairs TBI
outcome. Together, the results of this and the previous section support the idea that
mTORC1 overactivation after brain injury is indeed detrimental for recovery.
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Figure 3.12: Tsc2+/KO mice exhibit impaired memory in a context discrimination task
after a mCHI. A) Control SHAM animals learn the task after one training trial and
progressively get better at distinguishing between the two cages, (2-way repeated
measures ANOVA with cage and trial number day as between subject factors: group
main effect F(1,7)=34.515, p<0.001). B) Control mCHI mice acquire the task in two
trials, (2-way repeated measures ANOVA with cage and trial number as between
subject factors: F(2,16)=4.918, p=0.022). C) Tsc2+/KO mCHI mice three trials to learn
the task, (2-way repeated measures ANOVA with cage and trial number as between
subject factors: F(2,18)=6.139, p=0.009. Data represent means ± s.e.m., *p<0.05,
**p<0.01, ***p<0.001, †p<0.05, ‡p<0.001.

TSC2+/KO MICE RECOVER BY 5 WEEKS AFTER A MILD CLOSED HEAD INJURY

Brain injury causes acute as well as late repercussions. I have shown in the
previous sections of this chapter that mTORC1 activity increases in Tsc2+/KO but not
control littermates. This increase is correlated with a deficit in hippocampal-dependent
memory during the first few weeks after injury. However, mTORC1 is also known to
positively regulate brain plasticity and its increased activation, in TSC2+/KO mice, could
be beneficial for brain repair and recovery at later stages following injury.

My

hypothesis is that if increased mTORC1 activity positively regulates neuronal growth
and plasticity, then injured Tsc2+/KO mice will show better outcome at later stages
following CHI. To test this hypothesis a mild closed head injury was delivered to
Tsc2+/KO and Tsc2+/+ mice and learning and memory tested 5 weeks after injury (Fig
3.13).

Acute neurological tests and motor skills were not significantly different

between the two groups (Fig 3.14).
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Figure 3.13: Time line of experiments. Tsc2+/KO mice (n=10) and control littermates
(n=10) of 2-4 months of age were injured with a pneumatically driven controlled
cortical impact device. Immediately after the impact, acute neurological tests (apnea,
tail pinch response and righting response) were performed. On the first day after the
injury animals were tested on 2 motor skills tasks: paw placement and beam balance.
There was a break of 4 weeks and then during the fifth week after mCHI, animals were
trained and tested in a 1-day protocol of the Morris water maze. During the sixth week
after mCHI animals were trained and tested in a fear context discrimination task. At
the end of these behavioral tests, animals were killed and brains dissected for western
blot analysis.
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Figure 3.14: There is no substantial difference between Tsc2+/KO mice and control
littermates in acute neurological tests and motor skills after a mCHI. A sham group
(n=8) is shown for reference on each panel. A) There was no significant difference in
apnea between the two groups, 2-tailed, unpaired student’s t-test p=0.35. B) There
was no significant difference in tail pinch response between the two groups, 2-tailed,
unpaired student’s t-test p=0.3. C) Tsc2+/KO mice recovered from the righting response
significantly faster than their control litter mates after a mCHI, 2-tailed, unpaired
student’s t-test p=0.007. D) There was no significant difference in the paw placement
task between the two groups, (2-way repeated measures of ANOVA with group and
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training day as between subject factors: F(2,36)=1.578, p=0.22). E) There was no
significant difference in the beam balance task between the two groups, (2-way
repeated measures of ANOVA with group and training day as between subject factors:
F(2,36)=1.253, p=0.3. Data are represented as the mean ± s.e.m., **p<0.01.

Five weeks after suffering a mCHI, animals were trained in the Morris water
maze as specified in section 3.4. When long-term memory was tested 24 h after the
last trial, there was no difference between injured heterozygous Tsc2+/KO and injured
Tsc2+/+ mice in latency to find the platform location or number of crossing through the
platform area (Fig 3.15A and B). Furthermore, there was no difference between the
two groups when animals were trained and tested in a fear context discrimination task
(Fig 3.15C).

The previous section showed that Tsc2+/KO animals had impaired

hippocampal-dependent long-term memory when tested at subacute times (first 2-3
weeks after injury), suggesting that over activation of mTORC1 signaling exacerbates
TBI-associated learning and memory dysfunction. The results in this section show that
both groups of injured animals were able to accurately form hippocampus-dependent
long-term memories when tested in the chronic phase of injury. This indicates that
overactivation of mTORC1 does not cause lasting dysfunction. However, it is not
possible to say if mTORC1 overactivation is beneficial in the chronic phases after TBI
due to the fact that both groups recovered at the time tested.

68

Figure 3.15: Tsc2+/KO mice have no impairment in the MWM and context
discrimination tasks 5 weeks after a mCHI. A) There was no difference during learning
between the groups, (2-way repeated measures of ANOVA with group and training
trial as between subject factors: F(4,72)=0.633, p=0.6). No significant difference in a
probe trial given 24 hrs later was found, latency is shown (2- tailed, unpaired student’s
t-test; p=0.8). B) There was no significant difference in the number of crossings during
the probe trial (2- tailed, unpaired student’s t-test; p=0.2). C) Control SHAM mice
(left), Control mCHI mice (middle) and Tsc2+/KO CHI mice (right) froze significantly less
time in the safe cage than in the shock cage, after one day of training, indicating they
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could discriminate between them, (2- tailed, unpaired student’s t-test; Control SHAM,
p=0.006; Control CHI, p=0.036; Tsc2+/KO CHI, p=0.0095). Data represent means ±
s.e.m., *p<0.05, **p<0.01.

Tsc2+/KO animals showed a complete recovery 4-6 weeks after injury.

This

result could be due to a drop in mTORC1 activity levels. To test the possibility that
mTORC1 activity was reduced to baseline levels 6 weeks after injury, brain samples
were probed for phospho-S6 and phospho-ULK1 by western blot. My results show no
significant difference between injured and sham Tsc2+/KO animals (Fig 3.16A and B)
suggesting that the cognitive recovery observed could be attributed to mTORC1
activity return to baseline.
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Figure 3.16: pS6 and pULK1 levels return to baseline 6 weeks after a mCHI. Tsc2+/KO
mice (n=5) of 2-4 months of age were injured with a pneumatically driven controlled
cortical impact device and brain tissue dissected 6 weeks after the impact and
compared to a SHAM group (n=4). A) Top, Representative western blots. Bottom,
pS6 levels return to baseline 6 weeks after CHI, cortex (p=0.4) and hippocampus
(p=0.1) when compared to a sham group.

B) Top, Representative western blots.

Bottom, pULK1 levels return to baseline 6 weeks after CHI, cortex (p=0.3) and
hippocampus (p=0.98) when compared to a sham group. Data represent means ±
s.e.m., statistical analysis done by 2-tailed, unpaired student’s t-test

SUMMARY AND DISCUSSION

In this chapter, I investigated the effects of elevated mTORC1 activity of
Tsc2+/KO mice, on mild closed head injury (CHI) outcome.

I used hippocampal-

dependent learning and memory tasks to test cognitive deficits before and after the
trauma. My results show that Tsc2+/KO mice have elevated levels of phospho-S6, a
well-documented indicator of mTORC1 activity. However, Tsc2+/KO mice do not show
any learning and memory deficits in the Morris water maze or fear contextual
discrimination tasks. After CHI, elevated levels of phospho-S6 and phospho-ULK1 are
observed only in Tsc2+/KO mice but not control litter mates.

This acute (30 min)

overactivation of mTORC1, caused by a mild closed head injury, impairs long-term
memory formation within 2-3 weeks after the insult in Tsc2+/KO. Interestingly, 6 weeks
after injury, mTORC1 levels return to baseline and animals recover as well as control
littermates.

These results could aid in the design of treatments for brain-injured
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patients that differentially target the mTOR pathway in a temporally specific manner
following trauma.
The mTORC1 pathway is involved in synaptic plasticity necessary for memory
formation. Targeted inhibition of this pathway impairs memory and its misregulation, in
diseases like TSC, causes neuropsychological impairments as well. Among the first
TSC animal models to be discovered was the Eker rat.

These animals carry a

spontaneous germ line mutation in the Tsc2 gene, but only mild brain pathologies
have been observed. Consequently, these rats have minor behavioral deficits, have
no impaired hippocampal-dependent learning and memory and do not suffer epileptic
seizures (43, 195). In contradiction, a mouse model of TSC, created by mutating Tsc2
using gene targeting, showed long-term memory deficits for the standard version of
the Morris water maze and contextual fear discrimination (41, 145). A different TSC
mouse model containing a dominant negative allele of Tsc2 only showed mild
impairments in hippocampal dependent memory tasks (21, 57).

This variability in

results between rodent models of TSC could be caused by differences in background
between strains and species (104, 145).

It has also been suggested that brain

abnormalities in TSC patients develop due to a mutational “two-hit” model. Scientists
supporting the “two-hit” model argue that a second mutation in the functional Tsc1 or
Tsc2 allele, which produces loss of heterozygosity, is the mechanism for brain lesion
formation.

However, results supporting this view are contradictory with some

publications demonstrating the existence of mutations in both alleles (in tissue from
brain lesions only) and others suggesting that second hit mutations are rare
occurrences (28, 58, 70, 158).

Whether overactivation of mTORC1 pathway is

sufficient to produce cognitive impairments or they are caused by brain lesions is still
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unclear.

My results support the idea that Tsc2+/KO mice have no deficits in

hippocampal-dependent long-term memory formation even though mTORC1 activity
levels are elevated when compared to Tsc2+/+ control mice. However, Tsc2+/KO mice
provide an interesting model to test the hypothesis that, like a second-hit mutation, a
brain insult that further increases mTORC1 activity, would impair memory formation.
Traumatic brain injury (TBI) has been shown to produce acute elevation of
mTORC1 activity (20) but it is unclear if this finding is beneficial or detrimental to
outcome. After a brain injury, metabolic and molecular pathways may change in ways
that render the brain vulnerable to further injury or accelerate neurodegenerative
diseases.

The mTORC1 pathway holds a key role integrating cellular signals to

regulate both macromolecule biosynthesis and autophagy. Considering that protein
and lipid synthesis is necessary for the repair of damaged neuronal connections, one
might argue that increased mTORC1 activity would aid this processes. On the other
hand, active mTORC1 inhibits autophagy, also thought to play a role in cellular
responses to brain injury. Some studies suggest that inhibition of mTORC1 activity
improves TBI outcome, while others imply the opposite (44, 120, 147, 148). To further
understand the role of mTORC1 in TBI outcome, I delivered a mild closed head injury
to Tsc2+/KO mice. Uninjured Tsc2+/KO mice show elevated mTORC1 activity but no
cognitive impairments. When injured, Tsc2+/KO mice show further activation of the
mTORC1 pathway accompanied by memory deficits. The activation of mTORC1 was
measured by observing the levels of phospho-S6 (increased protein synthesis) and
phospho-ULK1 (decreased autophagy).

An increase in both S6 and ULK1

phosphorylation levels suggests that both processes are affected by mTORC1
dysregulation. Yet downstream signaling mechanisms could be interfering with the full
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activation or inactivation of these pathways. Therefore, it is still unclear whether active
protein synthesis or autophagy or both is the mechanism responsible for impaired
outcome after TBI. Future studies should be designed to understand the role of each
individual pathway in TBI outcome as well the cooperative effect they might show
when misregulated concomitantly.
Interestingly, after 4-6 weeks, mTORC1 levels return to baseline and
performance in the Morris water maze and fear context discrimination task are
comparable to control animals. This suggests that acute mTORC1 activity can be
detrimental for memory formation only after crossing an activation threshold. Whether
or not overactivation of mTORC1 could be beneficial in the chronic phases of TBI
remains unclear. Future experiments delivering moderate to severe injuries would aid
in this matter.
My results support the idea that mTORC1 overactivation has an important role
in TBI cognitive outcome. However, they do not exclude the possibility that mTORC1
is interacting with other signaling cascades to produce the observed deficit.
Apoptosis, cellular stress and inflammatory signals have also been shown to be
activated in response to brain injury (174). Consequently, the cognitive impairments I
observed could be due to mTORC1 interaction with other deregulated signaling
cascades.

TBI is a multi-system disorder, and as such a multi-target treatment

approach should be design.

However, the results from this chapter suggest that

decreasing mTORC1 activity in multiple cell types of the brain could be a potential
treatment for TBI. Further research is needed to understand how the interactions
between different signaling pathways and mTORC1 affect TBI outcome.
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It is estimated that 75% of all reported TBIs are classified as mild. Physicians
use a relatively straightforward definition of mild TBI set by The Centers for Disease
Control and Prevention, the World Health Organization and the United States Veterans
affairs/Department of Defense (35).

However, it has been difficult to establish a

defined criteria regarding mild TBI in experimental animals. A recent comprehensive
review, addressing the difficulties modeling mild TBI in the laboratory, suggests that
loss of consciousness could be a parameter to measure TBI severity (35). In rodents,
the duration to recover the righting reflex is considered an analogue to loss of
consciousness in humans. This test seems to be a good indicator of injury level and
the authors suggest that suppression of righting reflex between 5-20 min after injury
lacking any intracranial abnormalities should be classified as mild. The experimental
design related to this chapter held into account the possibility that a moderate to
severe closed head injury would mask any differences between Tsc2 +/KO and Tsc2+/+
mice due to a ceiling effect. My results show that righting reflex suppression never
extended more than 20 min and preliminary brain immunohistochemistry showed no
alterations in NeuN (cell loss), Nestin (reactive astrocytes) or Myeloperoxidase
(neutrophil infiltration) immunoreactivity (Not shown). Therefore, the severity of the
injury delivered to Tsc2+/KO mice and control littermates could be categorized as mild.
An interesting extension of my findings would be to repeat the above experiments but
administering a moderate to severe level of injury. Presumably, more severe injuries
would further increase mTORC1 levels acutely and extend the amount of time
mTORC1 remains overactive. In support of the conclusions from my results, I would
hypothesize that an even greater increase in mTORC1 activity following TBI would
further impair cognition. This would be seen as either a more pronounced dysfunction
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in hippocampal-dependent memory tasks and/or as a prolonged deficit, lasting weeks
to months. Prolonged overactive mTORC1 would be expected to reduce autophagy
and lysosomal biosynthesis, which can be detrimental to long-term recovery. This
could further our understanding of the molecular events and their function after TBI
and its progression.
In conclusion, my results demonstrate that when mTORC1 pathway is
compromised, a further insult to the system can lead to noticeable cognitive
impairments. This suggests that mTORC1 pathway could be a potential secondary
mechanism involved in brain vulnerability after TBI. However, my results show that its
activity is returned to basal levels at least as early as 6 weeks after mild closed head
injury. Further studies examining the effects of severe TBI as well as interactions
between mTORC1 and other molecular pathways after injury are needed to better
understand TBI pathology.
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CHAPTER 4

Glutamine reduces mTORC1 activity in
hippocampus and impairs memory formation
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INTRODUCTION

Proper translational control through the mechanistic Target of Rapamycin
Complex 1 (mTORC1) is required for normal expression of synaptic plasticity and
long-term memory (LTM) formation. mTORC1 integrates signals from many different
cellular inputs to regulate growth. When mTORC1 is active, it phosphorylates S6
protein kinase (S6K), which in turn phosphorylates ribosomal protein S6 (S6) and
eukaryotic initiation factor 4B (eIF4B) to activate translation (26, 160). These events
have been shown to also occur in dendrites, placing mTORC1 at a critical location for
translation-dependent synaptic plasticity (182, 183).
Rapamycin, a selective inhibitor of mTORC1, impairs several plasticity related
events like late-phase long-term potentiation (L-LTP) induced by high frequency
stimulation, synaptic potentiation induced by BDNF, and metabotropic glutamate
receptor-dependent long-term depression expression in hippocampal slices (74, 179,
183).

This same drug has been shown to block hippocampal long-term memory

formation in the Morris water maze task, the object recognition memory task, and
reconsolidation of inhibitory avoidance memory (31, 87, 88). Rapamycin infused in the
auditory cortex of Mongolian gerbils blocks consolidation of differential conditioning to
linearly frequency-modulated tones (188). When infused in the amygdala or medial
prefrontal cortex it inhibits delayed and trace fear conditioning memory respectively
(149, 180).

These results suggest that mTORC1 regulated protein synthesis is

required for normal long-term synaptic plasticity.
The TSC1/2 complex lies upstream of mTORC1 and acts as a point of
convergence for growth factors, hormones and ATP availability signals (36, 81).
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Supporting the idea that mTORC1 activity is required for LTM, when these pathways
are compromised, LTM is also inhibited. For example, blocking BDNF activity in the
rat dorsal hippocampus inhibits mTORC1 activation and impairs inhibitory avoidance
LTM (175). It has also been shown that insulin is capable of inducing Long-term
depression (LTD) and rapamycin inhibits insulin-dependent dendritic spine formation
(77, 115). Lastly, glucose increases phosphorylation of mTORC1 downstream targets
by inhibiting AMP kinase (AMPK), and enhancing LTM. Furthermore, AMPK activators
such as AICAR, 2-Deoxy-D-glucose and metformin, repress mTORC1 activity and
block LTP and LTM expression (31, 157). This suggests that mTORC1 integrates
these intracellular and extracellular signals to regulate protein translation required for
neuronal plasticity and long-term memory.
Unlike growth factors, hormones and ATP, amino acids regulate mTORC1
signaling through a pathway independent of TSC1/2. The mechanism by which amino
acids (leucine in particular) signal to mTORC1 is not well understood, although the
leucyl-RNA synthetase, class III phosphatidylinositol (PI) 3-kinase-Vps34, Ras-related
(Rag) guanosine triphosphatases (GTPases) and mitogen-activated protein kinase
kinase kinase kinase 3 (MAP4K3) have all been implicated (62, 101). In vitro studies
have shown that removing amino acids impairs mTORC1 signaling. When these are
added back into the cell culture individually, phosphorylation of mTORC1 targets
increases, with the strongest effect seen with leucine (33, 65, 82, 198). Leucine is the
best-studied mTORC1-activating amino acid, it alone can stimulate muscle protein
synthesis, and when infused into the rat brain it increases hypothalamic mTORC1
activity and decreases food intake and body weight (27, 159). In vitro administration of
glutamine, on the other hand, has produced variable results. Some studies suggest
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that glutamine inhibits mTORC1 signaling, others report that glutamine’s mTORC1
inhibitory effect can be antagonized by leucine and yet other studies have found no
difference in mTORC1 activity (33, 138, 142, 164). The variability in these results
could be explained by a recent finding by Nicklin et al. When cultured cells are amino
acid starved, addition of essential amino acids alone had very little effect on mTORC1
activity. However, when essential amino acids together with glutamine were added,
mTORC1 activity was significantly increased. Investigations on how amino acids enter
the cell suggest that the glutamine transporter SLC1A5 is responsible for increases
intracellular glutamine.

This glutamine is then exchanged for leucine through the

SLC7A5 amino acid bidirectional anti-porter.

Therefore, glutamine can indirectly

activate mTORC1 by facilitating leucine transport into the cell. It is still unclear why an
excess of glutamine could inhibit mTORC1. While these studies have been carried out
in amino acid deprived cells in culture, it remains unclear if glutamine can be used to
modulate mTORC1 signaling in the in-vivo brain in order to influence cognition.
My hypothesis is that if glutamine can inhibit mTORC1 activity in vivo, then
glutamine will impair memory formation.

To test this hypothesis I completed the

following specific aims:
I.

In vitro studies have shown that glutamine impairs mTORC1 activity of
starved cultured cells (33, 138).

Therefore I sought to determine if

glutamine could modulate the levels of phospho-S6 in non-starved cultured
cells.

Consequently, I tested whether intra-hippocampal infusions of

glutamine would decrease phospho-S6, indicating mTORC1 inhibition in
vivo.
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II.

Inhibition of mTORC1 with rapamycin impairs long-term memory formation
in a variety of behavioral tasks (18, 31, 87, 88, 188).

Therefore, I

investigated the possibility that intra-hippocampal infusions of glutamine
would impair long-term memory in the Morris water maze and fear context
discrimination.
III.

It is possible that glutamine’s effect on mTORC1 signaling is through an
indirect path by facilitating leucine access into the cell (140).

Since

glutamine and leucine have opposite effects on mTORC1 activity, one would
expect that co-administration of both amino acids would have a differential
effect than applying glutamine alone (33, 82, 138). For example, the effect
of one amino acid could win over the other or their effects would cancel
each other out. Therefore, I investigated the effect of intra-hippocampal coadminitration of glutamine and leucine on the levels of phospho-S6 and
long-term memory formation.

GLUTAMINE REDUCES mTORC1 ACTIVITY IN VIVO

Cell culture studies have shown that amino acids can regulate mTORC1
signaling under starvation or amino-acid free conditions (33, 82). However, starvation
conditions are not optimal when training and testing animals for cognitive tasks. For
this reason, I first tested if glutamine can influence on mTORC1 activity in bEnd.3 cells
under normal serum conditions. bEnd.3 cells are brain derived endothelial cells and
as such would be one of the first barriers for passage for molecules into the brain. To
determine if glutamine can affect mTORC1 signaling, bEnd.3 cells were normally
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grown until confluence. After reaching confluence, cells were pre-incubated for 2 hrs
with serum-free DMEM lacking glutamine or normal media, and then stimulated with
different concentrations of glutamine for 30 min. Under serum-free conditions, 5 mM
glutamine is sufficient to decrease the phosphorylation levels of the mTORC1 target
S6K (33).

Consistently, my results using bEnd.3 cells show that under starvation

conditions, 5 mM glutamine decreases the phosphorylation of S6K and S6 levels (Fig
4.1A and B).

However, when cells are kept in normal growth conditions, 5 mM

glutamine is unable to alter mTORC1 signaling. In order to determine if starvation is
necessary to influence mTORC1 activity, I performed dose-response studies using
increasing amounts of glutamine. Decreased phosphorylation levels of S6K and S6
were observed at 40 mM glutamine under normal serum culture conditions (Fig 4.1C
and D). This suggests that high concentrations of glutamine can potentially be used in
vivo to regulate mTORC1 signaling in the absence of food or amino acid deprivation.
Next, I investigated the ability of glutamine to decrease mTORC1 activity in
vivo. I performed targeted infusions aimed at the dorsal hippocampus. Rats were
infused with 1.3 µl of a 194 mM (37 µg) solution of glutamine into one dorsal
hippocampus and an equal volume of saline was administered simultaneously to the
contralateral dorsal hippocampus of the same animal. This dose was chosen based
on my previous experiment which suggested that high concentrations of glutamine
were necessary to affect mTORC1 activity in non-starved brain-derived cultured cells
(Fig 4.1). At 30 min after the completion of the infusion, rats were decapitated and the
hippocampi isolated and homogenized for high-performance liquid chromatography
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Figure 4.1: In vitro application of glutamine decreases phosphorylation of mTOR
targets in starved and non-starved bEnd.3 cells.
representative western blot samples are shown.

At the top of each figure
A and B) bEnd.3 cells under

starvation conditions for 2 hrs were treated with 0 mM or 5 mM glutamine, and lysates
collected 30 min later.

Glutamine administration significantly decreased mTOR

targets, S6K (A, 2-tailed, unpaired student’s t-test; p<0.018) and S6 (B, 2-tailed,
unpaired student’s t-test; p=0.042), phosphorylation but not their total protein levels. C
and D) bEnd.3 cells under normal culture conditions were treated with 0 mM, 5 mM or
40 mM glutamine, and lysates collected 30 min later. 40 mM, but not 5 mM, glutamine
treatment significantly decreased mTOR targets, S6K (C, One-way ANOVA
F(2,6)=9.048, p<0.015) and S6 (D, One-way ANOVA F(2,6)=9.406, p=0.014),
phosphorylation. Total protein levels did not change significantly. Data represent
means ± s.e.m of immunoreactivity percentage corrected against β-actin loading
control, *p<0.05.

(HPLC) and western blot analysis.

Figure 4.2A shows that glutamine content is

increased 2.5 fold in hippocampal tissue extracts 30 min after infusion. Importantly,
glutamate, a prominent excitatory neurotransmitter that can be synthesized from
glutamine, did not show any changes at the time tested. Figure 4.2B and 1C show
representative Western blots and summary data indicating that glutamine infusion
caused a significant decrease in the phosphorylation, but not the total levels, of S6
(Fig 4.2C).

The phosphorylation levels of S6K trended down but did not reach

statistical significance (Fig 4.2B).

To discard the possibility that non-specific,

generalized effects were responsible for this result, I tested the samples for
phosphorylation levels of upstream protein regulators of mTORC1 signaling.
Phospho-Tsc2, phospho-AMP activated protein kinase and phospho-mitogen activated
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protein kinase levels were not affected after glutamine administration (Fig 4.3). These
results indicate that glutamine can be used to manipulate mTORC1 activity in vivo.
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Figure 4.2: In vivo Intrahippocampal administration of glutamine decreases mTOR
activity.

A) Intrahippocampal infusions of glutamine (52 μg/hippocampus, n=3) or

vehicle (saline) were administered and brain extracts collected 30 min later to be
analyzed by HPLC. Glutamine administration significantly increased its brain levels (2tailed, unpaired student’s t-test; p=0.008) but not the levels of glutamate (2-tailed,
paired student’s t-test; p=0.14). B and C) Intrahippocampal infusions of glutamine (37
μg/hippocampus, n=6) or vehicle (saline) were administered and samples collected 30
min later.

Glutamine administration significantly decreased mTOR target S6

phosphorylation (C, 2-tailed, paired student’s t-test; p=0.049) but not its total protein
level.

Phosphorylation levels of S6K (B, 2-tailed, paired student’s t-test; p=0.16)

trended downward but did not reach significance.

To the left of each figure

representative western blot samples are shown.

Western blot graphs show

quantification corrected against β-actin loading control.

Data represent means ±

s.e.m, *p<0.05.
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Figure 4.3: Intrahippocampal administration of glutamine does not affect the levels of
pTSC2, pAMPK or pMAPK.

Intrahippocampal infusions of glutamine (37

μg/hippocampus, n=6) or vehicle (saline) were administered and samples collected 30
min later.

Glutamine administration did not significantly affect the phosphorylation

levels of upstream mTORC1 signaling proteins TSC2 and AMPK or MAPK.

GLUTAMINE IMPAIRS SPATIAL AND CONTEXTUAL MEMORY

Agents known to inhibit the mTORC1 pathway, like Rapamycin, have been
shown to impair long-term memory.

Consistent with in vitro studies, my findings

suggest that high levels of brain glutamine can cause a decrease in mTORC1 activity,
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as indicated by reduced phosphorylation of downstream targets (Fig 4.2C).
Consequently, I posit that increasing brain glutamine may impair LTM. I performed the
hidden platform version of the Morris water maze task to test this prediction. Animals
were trained and immediately after reaching criterion (three consecutive trials <10 s),
were infused bilaterally with 37 µg/hippocampus glutamine (n = 7) or an equal volume
of vehicle (n = 8). When tested for long-term memory in a retention test 48 h after
training, the glutamine-treated group showed no difference in latency to the original
platform location but crossed the platform location significantly fewer times (glutamine
0.74 ± 0.18 crossings; vehicle 1.87 ± 0.44 crossings, p = 0.038) (Fig 4.4A and B). This
suggests that the glutamine-infused animals had an impaired memory of the platform
location. In addition to the number of crossings to the platform location, a significant
interaction of group by location was detected between the two groups in the time spent
in concentric circles of decreasing diameter centered around the platform location
(F(3,36)= 5.015, p = 0.005). Post-hoc analysis revealed that this interaction was due to
the vehicle-infused animals spending more time in the immediate vicinity of the
platform, whereas glutamine-infused animals searched in a wider area further from the
platform (indicated by *, Fig 4.4D). This is visually shown by representative traces of
the swimming paths taken by a glutamine-treated animal and a vehicle-treated animal
during the probe test (Fig 4.4C). These differences were not attributable to changes in
swimming speed (Fig 4.4E) or visual/motivational impairments (Fig 4.4F).

These

results were reproduced with an even stronger impairment of LTM when 52
µg/hippocampus glutamine was infused (Fig 4.5).

When animals infused with 52

µg/hippocampus glutamine were tested for long-term memory in a retention test 48 h
after training, the glutamine-treated group showed a significant difference in latency to
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Figure 4.4: Post-training intrahippocampal administration of glutamine (37 µg) impairs
long-term spatial memory.

A) Rats were trained in a 1-day Morris Water Maze

protocol and infused with either vehicle solution (n=8) or 37 μg/hippocampus of
glutamine (n=7) immediately after the last training trial. A probe trial was given 48 hrs.
later. Latency to locate the hidden platform is shown, (2-tailed, unpaired student’s ttest; p=0.5). B) The number of crossings of the previous platform location during the
probe trial is shown, (2-tailed, unpaired student’s t-test; p=0.038). C) Representative
probe trial traces of a vehicle and a glutamine-infused animal showing the path taken.
D) Dwell time in counter areas of decreasing diameters (4X, 3X and 2X platform
radius) during the probe trial, (two-way repeated-measures of ANOVA with treatment
and ring number as between-subjects factors: F(3,36)=5.015, p=0.005).

E) Swim

velocity, (2-tailed, unpaired student’s t-test; p=0.9). F) Latency to a visual platform
performed after the probe trial, (2-tailed, unpaired student’s t-test; p=0.6).
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Figure 4.5: Post-training intrahippocampal administration of glutamine (52 μg) impairs
long-term spatial memory.

A) Rats were trained in a 1-day Morris Water Maze

protocol and infused with either vehicle solution (n=9) or 52 μg/hippocampus of
glutamine (n=8) immediately after the last training trial. A probe trial was given 48 hrs.
later, latency is shown, (2-tailed, unpaired student’s t-test; p=0.04). B) A probe trial
given 48 hrs. later, number of crossings is shown, (2-tailed, unpaired student’s t-test;
p=0.03). Inset: Representative probe trial traces of a vehicle and a glutamine-infused
animal during probe trial 2 showing the path taken. C) Number of entries to counter
areas of decreasing diameters (4X, 3X and 2X platform radius) during the probe trial,
(two-way repeated-measures of ANOVA with treatment and ring number as betweensubjects factors: group main effect F(1,15)=8.412, p=0.011). D) Dwell time in counter
areas of decreasing diameters (4X, 3X and 2X platform radius) during the probe trial,
(two-way repeated-measures of ANOVA with treatment and ring number as betweensubjects factors: group main effect F(1,15)=10.052, p=0.006). E) Latency to counter
areas of decreasing diameters (4X, 3X and 2X platform radius) during the probe trial,
(two-way repeated-measures of ANOVA with treatment and ring number as betweensubjects factors: group main effect F(1,15)=4.818, p=0.044). F) Swim velocity during
probe trial 2, (2-tailed, unpaired student’s t-test; p=0.5).

G) Latency to a visual

platform performed after probe trials, (2-tailed, unpaired student’s t-test; p=0.36).
*p<0.05, **p<0.01, †p<0.05, ‡p<0.01. Data represent means ± s.e.m.

the original platform location (glutamine 56.1 ± 3 latency; vehicle 34.6 ± 8.7 latency, p
= 0.04) (Fig 4.5A), and crossed the platform location significantly fewer times
(glutamine 0.9 ± 0.2 crossings; vehicle 0.25 ± 0.16 crossings, p = 0.03) (Fig 4.5B).
This support the previous finding, that the glutamine-infused animals had an impaired
memory of the platform location.

In addition, a significant group main effect was

detected between the two groups in the number of entries (Fig 4.5C), time spent (Fig
4.5D) and latency (Fig 4.5E) to concentric circles of decreasing diameter centered
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around

the

platform

location

(entries,

F(1,15)=8.412,

p=0.011;

F(1,15)=10.052, p=0.006; latency F(1,15)=4.818, p=0.044).

dwell

time

Post-hoc analysis

revealed that this group difference was due to the vehicle-infused animals spending
more time in the immediate vicinity of the platform, whereas glutamine-infused animals
searched further from the platform (indicated by *, Fig 4.5C, D and E). This is visually
shown by representative traces of the swimming paths taken by a glutamine-treated
animal and a vehicle-treated animal during the probe test (Fig 4.5B inset). These
differences were not attributable to changes in swimming speed (Fig 4.5F) or
visual/motivational impairments (Fig 4.5G).
To further confirm that intra-hippocampal glutamine infusions have a detrimental effect
on LTM, rats were trained in a contextual delayed fear conditioning task. Animals
were presented with a tone for 30 seconds at the end of which they received a 2 s-0.8
mA shock. They were given 3 trials separated by 1 min in the training chamber.
Immediately after training the rats were infused with 37 µg/hippocampus glutamine (n
= 11) or an equal volume of vehicle (n = 9). There was no difference in baseline
freezing between the two groups (Fig 4.6A left).

Memory was tested 48 h after

training; there was no difference between the groups when they were exposed to the
training tone, a hippocampus independent memory (Fig 4.6A right). When tested for
contextual memory, the two groups displayed similar freezing behavior in the training
chamber (Fig 4.6B left). However, when fear was assessed in a novel context that
shared similar features with the training cage while differing in others, the glutamineinfused animals displayed a significantly higher freezing behavior than the vehicle
infused animals (glutamine 24.14 ± 4.35 % freezing; vehicle 7.28 ± 1.72 % freezing, p
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= 0.004) (Fig 4.6B right). This suggests that glutamine-infused rats had problems
distinguishing between the two chambers.

Figure 4.6: Post-training intrahippocampal administration of glutamine (37 µg) impairs
long-term contextual fear memory. Rats were trained in a delay fear conditioning
paradigm and infused with either vehicle solution (n=9) or 37 μg/hippocampus of
glutamine (n=11) immediately after the last training trial. A test was given 48 hrs.
later. A) Left, % time freezing is shown for baseline conditions (2-tailed, unpaired
student’s t-test; p=0.4). Right, % time freezing in a completely different novel context
and exposed to the training tone (2-tailed, unpaired student’s t-test; p=0.6). B) Left, %
94

time freezing in the training context (2-tailed, unpaired student’s t-test; p=0.3). Right,
% time freezing in a novel but similar context (2-tailed, unpaired student’s t-test;
p=0.004). Data represent means ± s.e.m., *p<0.05, **p<0.01.

CO-ADMINISTRATION OF LEUCINE WITH GLUTAMINE REVERSES GLUTAMINE
ALONE EFFECTS

Intra-hippocampal leucine increases mTORC1 activity but has no effect on memory
formation

Previous studies have shown that leucine can activate mTORC1 in vitro, and
that brain infusions of leucine in fasted rats can also increase mTORC1 signaling (27,
82). To determine if leucine can activate hippocampal mTORC1 in non-fasted rats, I
infused 1.5 µl of a 137 mM solution (27 µg) of leucine into one dorsal hippocampus
and an equal volume of saline was administered simultaneously to the contralateral
dorsal hippocampus of the same animal. Figure 4.7A and 3B show representative
western blots and summary data indicating that a significant increase in the
phosphorylation, but not the total levels, of the translational regulators S6K and S6
was detected when leucine was administered.
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Figure 4.7: Intrahippocampal administration of leucine increases mTOR activity.
Intrahippocampal infusions of leucine (27 μg/hippocampus, n=5) or vehicle (saline)
were administered and samples collected 30 min later. A) Leucine administration
significantly increased phosphorylation of mTORC1 target, S6K (A, 2-tailed, paired
student’s

t-test;

p=0.03)

B)

Leucine

administration

significantly

increased

phosphorylation of mTORC1 target S6 (B, 2-tailed, paired student’s t-test; p=0.01), but
not their total protein levels. Data represent means ± s.e.m., *p<0.05.

Based on the results obtained in the previous experiment, it was anticipated
that leucine, via activation of mTORC1, would cause an improvement in memory. To
test this possibility, rats were trained in the hidden platform version of the Morris water
maze.

Immediately after reaching criteria the rats were infused with 13

µg/hippocampus leucine (n = 10; supplemental Fig 4.8A and B), 27 µg/hippocampus
leucine (n = 10; Fig 4.8 C and D) or an equal volume of vehicle (n = 11). When they
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were tested for LTM during a retention test 48 h after training, there was no difference
between the amino acid- and vehicle-infused animals (leucine 13 µg 35.6 ± 4 latency,
1.45 ± 0.3 crossings ; vehicle 37.2 ± 4 latency, 1.5 ± 0.4, p = 0.6), (leucine 27 µg 16.6
± 7 latency, 1.7 ± 0.3 crossings; vehicle 28.5 ± 6 latency, 2.1 ± 0.3, p=0.7 and p = 0.18
latency and crossings respectively) (Fig 4.8). No difference was also observed when a
less robust training criterion (three consecutive trials with an average of <15 s platform
latency) was used (data not shown), one that has been previously used for agents that
enhance LTM (31), suggesting that a possible transient increase in mTORC1 activity
induced by leucine has no effect on LTM.
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Figure 4.8: Post-training intrahippocampal administration of leucine has no effect on
long-term spatial memory.

A) Rats were trained in a 1-day Morris Water Maze

protocol and infused with either vehicle solution (n=11) or 13 μg/hippocampus of
leucine (n=10) immediately after the last training trial. A probe trial was given 48 hrs.
later, latency to cross the previous location of the platform is shown, (2-tailed, unpaired
student’s t-test; p=0.6). B) A probe trial given 48 hrs. later, number of crossings of the
previous platform location is shown, (2-tailed, unpaired student’s t-test; p=0.6). C)
Rats were trained in a 1-day Morris Water Maze protocol and infused with either
vehicle solution (n=11) or 27 μg/hippocampus of leucine (n=10) immediately after the
last training trial. There was no difference in a probe trial given 48 hrs. later, latency
is shown, (2-tailed, unpaired student’s t-test; p=0.7). D) There was no difference in
number of crossings during the probe trial, (2-tailed, unpaired student’s t-test; p=0.18).
E) Left, representative schematics showing intrahippocampal infusion sites (black
dots). Right, representative picture of cannula placement. Data represent means ±
s.e.m.

Glutamine effects can be overcome by co-administration with leucine

As my results show that leucine and glutamine have opposing influences on
mTORC1 activity, I tested the effect of co-infusion of these amino acids. To determine
the effect of co-administration of leucine and glutamine on mTORC1 signaling, 30 min
post-infusion extracts were compared to the contralateral hippocampi infused with
vehicle. Figure 4.9A and B show representative western blots and summary data
demonstrating that when leucine and glutamine are co-infused, there is no effect on
mTORC1 activity. As indicated by no change in the phosphorylation levels of S6K and
S6.
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Figure 4.9: Intrahippocampal co-administration of leucine and glutamine blocks effects
of single amino acid infusion on mTOR activity.

A and B) Intrahippocampal co-

infusions of leucine and glutamine (27μg/hippocampus, 52 μg/hippocampus
respectively, n=5) or vehicle (saline) were administered and samples collected 30 min
later. There was no significant effects in the levels of pS6K or total S6K (C, 2-tailed,
paired student’s t-test; p=0.8, p=0.4, respectively). There were no significant effects
on the levels of pS6 or total S6 (D, 2-tailed, paired student’s t-test; p=0.6, p=0.9,
respectively). Data represent means ± s.e.m.

To determine whether the lack of an effect on mTORC1 activity when leucine
and glutamine are co-infused into the hippocampus also affected the behavioral
outcome, I again performed the Morris water maze task. Animals were trained and
immediately after reaching criterion (three consecutive trials <10 s), were infused
bilaterally with 27 µg leucine and 52 µg glutamine/hippocampus (n = 9) or an equal
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volume of vehicle (n = 9). When they were tested for long-term memory in a retention
test 48 h after training, the amino acid-treated group showed no difference in latency
to the original platform location or the number of times it crossed the platform location
(amino acids 29.3 ± 10.4 latency; vehicle 34.6 ± 8.7 latency, p = 0.7 and amino acids
1.4 ± 0.56 crossings; vehicle 1 ± 0.2 crossings, p = 0.5) (Fig 4.10A and B). Further
analysis revealed that both groups of animals developed a similar search pattern. This
is shown by their time spent in counter areas of decreasing diameter around the
platform location (F(3,48)= 0.663, p = 0.579) (Fig 4.10C). This suggests that when both
amino-acids are increased in the brain, mTORC1 activity is not altered and LTM is not
altered. After completion of the behavioral testing, animals were killed and their brains
were analyzed for infusion site accuracy.

Fig 4.10D shows the locations of the

intrahippocampal infusion sites for representative animals used in the Morris water
maze study.
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Figure 4.10: Post-training intrahippocampal co-administration of leucine and
glutamine blocks effects of single amino acid infusion on long-term spatial memory
formation. A) Rats were trained in a 1-day Morris Water Maze protocol and infused
with

either

vehicle

solution

(n=9)

or

27μg/hippocampus

of

leucine

and

52μg/hippocampus of glutamine (n=9) immediately after the last training trial. There
was no significant difference in a probe trial given 48 hrs. later, latency is shown, (2tailed, unpaired student’s t-test; p=0.7). B) There was no difference in number of
crossings during the probe trial, (2-tailed, unpaired student’s t-test; p=0.5). C) Dwell
time in counter areas of decreasing diameters (4X, 3X and 2X platform radius) during
the probe trial, (two-way repeated-measures of ANOVA with treatment and ring
number as between-subjects factors: interaction F(3,48)=0.663, p=0.579).

D)
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Representative schematics showing intrahippocampal infusion sites (black dots). Data
represent means ± s.e.m.

SUMMARY AND DISCUSSION

The findings from the present study demonstrate for the first time the
association between glutamine effects on brain mTORC1 regulation and long-term
memory.

Specifically, I show that the amino acid glutamine impairs long-term

memory, an effect that can be mitigated by co-administration of the branch-chain
amino acid leucine.

These behavioral consequences are consistent with the

influences of these amino acids on the mTORC1 pathway, and suggest that leucine
and/or glutamine supplementation may have value in conditions associated with
mTORC1 misregulation.
In vitro studies have shown that mTORC1 activity responds to the availability of
amino acids.

Specifically, cell culture studies have demonstrated that removal of

amino acids causes suppression in mTORC1 activity that can be reverse by addition
of branched chain amino acids, with the more potent effects observed following
leucine application. Glutamine, by comparison, has been demonstrated to reduce
mTORC1 activity or block the influence of leucine depending on the cell type
examined.

However, glutamine also plays an important role in the activation of

mTORC1 aiding in the entry of leucine into the cell (140).

Although systemic

administration of leucine has been shown to enhance mTORC1 activity in skeletal
muscle, there has been only one study indicating that leucine infusions into the brain
can activate this pathway (27, 33, 65, 82, 138, 159, 164). In all of these studies, the
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cells or animals were starved or food restricted prior to the treatment. No studies have
been published addressing in vivo glutamine modulation of mTORC1.

As food

deprivation and dietary restrictions have been shown to influence cognitive function, I
questioned if glutamine could influence mTORC1 activity in brains of normally fed rats
(66, 143).

I observed that intrahippocampal infusions of leucine enhanced, while

glutamine inhibited, mTORC1 activity. When administered concurrently, no influence
on mTORC1 activity was detected.

This is the first report to indicate that

administration of amino acids to non-food deprived animals can be used to modulate
mTORC1, supporting their use as nutritional supplements.
My results show that high concentrations of glutamine, when infused directly
into the brain, inhibit mTORC1 activity and impair both long-term spatial and
contextual memory.

Glutamine is very abundant in the brain where it acts as a

precursor for neurotransmitters like glutamine and GABA (6, 197). It is possible that
the effects I observed on LTM, as a result of glutamine administration, were due to an
increase in the levels of these neurotransmitters. However, when samples obtained
from glutamine-infused rats were assessed for glutamate levels, no significant
differences were observed. Further, the memory impairment seen following glutamine
administration was not observed in rats co-administered leucine, an effect not
expected if glutamine altered GABA levels. Although the reason for this apparent
opposite effects is not clear, it has been suggested that glutamine may regulate
leucine availability. Therefore, an imbalance in the concentrations of these two amino
acids may be responsible for the changes in mTORC1 activity I observed (140).
It was expected that leucine would enhance memory formation due to its effect
on increased mTORC1 activity. Contrary to this prediction, leucine had no effect on
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long-term spatial memory formation. This result suggests that even though this amino
acid was able to upregulate mTORC1, this effect was not sufficient to alter long-term
memory.

Previous studies have suggested that high levels of brain leucine are

detrimental to memory formation. For example, using a model of Maple syrum urine
disease in which the branched-chain amino acids -leucine, isoleucine and valine- were
administered subcutaneously twice daily for 21 days, Scaini et al. reported impaired
habituation in the open field task and disturbed object recognition memory.

The

authors of this study observed that chronic leucine caused a persistent increase in
BDNF levels, which is thought to accelerate excitotoxic neuronal necrosis (169).
Using intra-hippocampal administration of leucine (10.5 µg), Glaser et al. reported
impaired long-term memory in a step-down task, an effect associated with changes in
mitochondrial function (56). Taken together, these findings suggest that changes in
brain leucine concentrations may have differential effects on LTM depending on
treatment length and the behavioral task performed.
In conclusion, the results presented in this chapter suggest that the amino acids
glutamine and leucine act as signaling molecules to regulate the mTORC1 pathway
and could potentially be used as dietary supplementations in disorders in which
mTORC1 is misregulated.
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CHAPTER 5

Oral glutamine extends survival of Tsc2
conditional knock-out mice
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INTRODUCTION

The importance of the TSC-mTORC1 pathway in LTM is clearly evident when
its

disruption

results

in

neurological

disorders.

These

disorders

include

neurofibromatosis type 1, PTEN associated macrocephaly, Fragile X syndrome and
Tuberous Sclerosis Complex (TSC) (109, 116, 139).
Increased mTORC1 activity, resulting from either loss of TSC1 or TSC2
proteins, results in TSC, an autosomal dominant disorder (19, 29). Patient population
studies have shown that TSC2 gene mutations account for 60% of TSC patients, while
only 30% express TSC1 mutations (90, 91). Some studies have reported that patients
with a mutation in TSC2 have more severe neurological pathologies than patients with
TSC1 mutations. A recent study comparing Tsc1 and Tsc2 conditional knock-out mice
supports this view. Even though the mechanistic basis for this difference is not known,
one could hypothesize that since tuberin contains the GTPase activating protein
domain of the TSC molecular complex, then mutations in Tsc2 would have more
severe phenotypes than mutations in Tsc1 (207).
Heterozygous mouse models lacking Tsc1 or Tsc2 eventually manifest renal
tumors but have no major central nervous system pathologies, which are the main
cause of morbidity and mortality in TSC patients. Homozygous Tsc1 or Tsc2 mice are
embryonic lethal (71, 105, 106).

To better understand how TSC causes brain

abnormalities that result in seizures and learning and behavioral deficits, conditional
homozygous brain disruptions of Tsc1 and Tsc2 have been developed.

Genetic

mouse models that affect developmental stages have severe phenotypes including
megancephaly, cortical and hippocampal lamination defects, enlarged dysplastic
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neurons and glia, abnormal myelination and astrocytosis. These mice die within 1-2
months of being born (28, 191, 200, 207).

Conditional mouse models using the

CamK2a promoter driven Cre recombinase bypass the embryonic and developmental
stages and present less severe brain pathologies. For example, Tsc1flox/flox;CamK2acre mice have enlarged brains due to massive neuronal hypertrophy and present
astrogliosis. Behaviorally they show an abnormal hindlimb clasping reflex and are
hypoactive compared to control littermates. These mice also die within their first 3
months of age (41).
Rapamycin and other mTORC1 inhibitors are being studied as potential
treatments for misregulated mTOR-driven disorders (15, 42, 49). For example, the
lethality observed in mouse models of TSC can be mitigated by daily administration of
rapamycin (201) and its use for the treatment of subependymal giant cell astrocytomas
associated with TSC has been approved by the Federal Drug Administration (48).
Thus, identification of additional agents that can regulate mTORC1 activity in vivo may
have both basic science and translational value.
In the previous chapter I showed that glutamine can impair long-term memory
formation when infused into the hippocampus and this is correlated with a decrease in
mTORC1 activity. My hypothesis is that if in vivo administration of glutamine can
inhibit mTORC1 signaling, then it could be used to extend life in Tsc2 flox/flox;CamK2acre (Tsc2CKO) mice. To test this hypothesis I completed the following specific aims:
I.

Although the blood brain barrier is designed to remove glutamine from the
brain, studies show that high concentrations of oral glutamine increase brain
glutamine levels (67, 197). In addition, I have shown that glutamine can
decrease mTORC1 activity when infused into the hippocampus. Therefore,
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I aimed to evaluate the efficacy of oral glutamine to attenuate mTORC1
signaling in Tsc2CKO mice hippocampi.
II.

Tsc1flox/flox;CamK2a-cre mice die within 3 months of age but treatment with
rapamycin can decreased mTORC1 activity and extend their life span.
Therefore, I tested the possibility that oral glutamine would extend lifespan
of Tsc2CKO mice.

CHARACTERIZATION OF TSC2FLOX/FLOX; CAMKIIA-CRE MICE

Conditional knock-out mouse models of TSC show several brain pathologies as
well as behavioral deficits (28, 41). To assess the severity of brain and behavioral
pathologies in Tsc2CKO mice, animals were monitored once daily. Weight, physical
appearance (coat appearance, nasal/ocular discharge, abnormal posture) and general
behavior (hindlimb clasping reflex, reduced mobility, isolationism, mutilation, and
restlessness) were recorded. Tsc2CKO mice did not show any differences in weight
gain (Fig 5.1B), coat appearance or any other physical attribute.

General cage

behavior also appeared normal, animals were seen grooming, being groomed and no
mobility impairments were noted. Occasionally animals would react to manipulation
with uncontrolled jumping, extreme movement of extremities and loud vocalizations;
these events were noted as seizures.

Abnormal hindlimb clasping reflex was

observed immediately before or after a seizure episode (Fig 5.1A) but was otherwise
normal. Finally, preliminary histological studies did not show any overt differences in
neuronal size or lamination defects.

Tsc2CKO mice showed enhanced pS6
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expression levels in the hippocampus when compared to control littermates and died
within 3 months of age.

Figure 5.1: Tsc2CKO mice hindlimb clasp and weight gain. A) Tsc2CKO mice often
show a hindlimb clasp (arrow) close to the beginning or after a seizure. Top, control
littermate mouse with normal reaction to being lift by the tail. Middle and bottom,
abnormal response, hindlimb clasp, indicative of neurological impairment. B) There is
no significant difference between Tsc2CKO mice and control littermates in weight gain.
Data represent means ± s.e.m.

ORAL GLUTAMINE REDUCES mTORC1 ACTIVITY AND EXTENDS SURVIVAL OF
TSC2FLOX/FLOX; CAMKIIA-CRE MICE

Genetic experimental models of tuberous sclerosis complex, like Tsc1 and Tsc2
conditional knock-out mice, show elevated levels of mTORC1 activity due to the lack
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of TSC-TBC complex repression.

Reducing mTORC1 activity with rapamycin

improves their survival (Ehninger et al.

2008; Way et al.

2012).

The results

presented in the previous chapter, suggest that glutamine has mTORC1 inhibiting
properties as well and could potentially be used to treat diseases in which mTORC1 is
misregulated, like TSC. For this reason, Tsc2CKO mice of 1 month of age, were
administered 3 g/kg glutamine (n=5) or an equal volume of saline (n=5) via gavage
twice a day (morning and afternoon), 5 days per week for 2 weeks. A third group of
control littermates was used to establish normal levels of pS6. At the end of the 2
weeks and 1 h after the last dose, animals were killed and their brains removed to be
fixed for immunohistochemistry.

Tissues probed with an antibody against

phosphorylated S6 (Ser240/244) showed higher immunoreactivity in the hippocampus
of vehicle treated mice, particularly the DG and CA1 regions when compared to control
littermates (Fig 5.2 A first and second panels). This was expected due to the lack of
Tsc2, which results in over activation of mTORC1. Interestingly, the glutamine treated
samples show reduced phospho-S6 immunoreactivity in the DG, but not CA1, when
compared to vehicle treated mice.
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Figure 5.2: Oral glutamine decreases hippocampal mTORC1 activity in CamKII-Tsc2
Conditional KO mice. A) Representative samples showing CamKII-Tsc2 Conditional
KO mice with increased mTORC1 activity in hippocampus than control littermates
(Right first and second pictures). This is most evident in CA1 and DG regions. B) Oral
administration of glutamine (3 g/kg twice daily) significantly decreases the
phosphorylation levels of S6 in DG (Left top, One-way ANOVA F(2,11)=9.017, p=0.005)
but not NeuN (Left bottom, One-way ANOVA F(2,11)=0.341, p=0.718). Data represent
means ± s.e.m.

As Tsc2CKO mice die prematurely, I questioned if glutamine administration can
improve survival, as has been seen with rapamycin. Mice were treated with glutamine
as described above (n=11 per group) until death was noted. My results show that
there was a statistical difference between the Kaplan-Meier survival curves of
glutamine and vehicle treated animals (Fig 5.3B). It can be observed that the lethal
time at which 50% of the Tsc2CKO animals die (LT50) was prolonged by
approximately 2 weeks in the glutamine treated group. These results suggest that
glutamine administration can lower mTORC1 activity in the dentate gyrus, as well as
prolong the life span of Tsc2CKO mice.
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Figure 5.3: Oral glutamine extends survival in CamKII-Tsc2 Conditional KO mice.
Kaplan-Meier survival curves show how oral glutamine administration (3 g/kg twice
daily) significantly extends survival of CamKII-Tsc2 Conditional KO mice (n=11/group,
Log Rank test, p=0.044). Dashed line indicated time at which 50% of animals die.

SUMMARY AND DISCUSSION

To the best of my knowledge, this is the first study indicating that oral glutamine
treatments could be used to improve the morbidity and mortality of mTORC1
associated disorders such as TSC.

In the previous chapter, I showed that intra-

hippocampal glutamine impairs long-term memory, an effect that can be reversed by
co-administration of leucine.

These cognitive consequences, which are consistent

with the influences of these amino acids on the mTORC1 pathway, suggest that
leucine and/or glutamine supplementation may have value in conditions associated
with mTORC1 misregulation.

Supporting this idea, I showed that oral glutamine
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administration lowered mTORC1 activity levels of Tsc2CKO mouse brains and
prolonged their life span.
Animals were given 6 g/kg of daily glutamine based on the assumption that high
levels of glutamine would be needed to influence mTORC1 signaling in the brain (see
results from previous chapter). However, this amount of glutamine would be
inconvenient for a human patient to consume on a daily basis (an average 85 kg
person would need to consume 510 g of glutamine). Future studies should be done to
determine the optimal glutamine dose and most efficient route of administration
needed to decrease mTORC1 activity.
Glutamine treatment has been shown to be effective in the recovery from
trauma, cancer chemotherapy, alcohol withdrawal and has been used to treat Sickle
Cell Anemia (5, 92, 141, 178). The widespread metabolic roles of glutamine allows for
its boundless effects. For example, the rapid depletion of glutamine after catabolic
stress caused by trauma, sepsis or burns makes it conditionally essential and its
administration results in reduced rates of inflammation, infection, hospital stay and
mortality (100). Additionally, glutamine’s role in ammonia detoxification has made its
synthesis and deamidation a target for the treatment of hepatic encephalopathy (92,
161). My results suggest a new role for glutamine as an mTORC1 inhibitor. Tsc2CKO
animals have higher levels of mTORC1 activity due to the lack of the mTORC1
negative regulator complex TSC1-TSC2.

When these animals are given oral

glutamine, mTORC1 activity is reduced and their life span is prolonged by about 2
weeks.
In vitro studies have shown that glutamine can influence mTORC1 signaling
through either the Rag GTPases by facilitating leucine access into the cell or through
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the AMPK-TSC1/2-Rheb pathway by entering the Krebs cycle after glutaminolysis
(102). These studies suggest that glutamine is necessary for mTORC1 activation.
However, studies have shown that glutamine inhibits mTORC1 signaling in cultured
cells (33, 138).

It seems that glutamine can either activate or inhibit mTORC1

signaling depending on the concentration used. An extension of this study would be to
better define the amount of oral glutamine that could enhance, instead of inhibit,
mTORC1 activation.
The mTORC1 pathway has been implicated in several diseases including
cancer, Alzheimer’s disease, Parkinson’s disease, and tuberous sclerosis complex
amongst others (23). My results suggest that manipulation of glutamine and leucine
may have benefit in the treatment of these diseases due to their roles as mTORC1
regulators. Further studies will be required to fully explore these possibilities.
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CHAPTER 6

General discussion
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SUMMARY OF FINDINGS AND FUTURE DIRECTIONS

The ability of mTORC1 signaling to integrate nutritional, energy and stress
signals to regulate cellular health and survival, make this pathway an important target
for several diseases. In this thesis, I have furthered our understanding of the role
mTORC1 plays in memory formation and memory dysfunction.
In Chapter 3, I showed that a heterozygous deletion of Tsc2 increases
mTORC1 activity. This increase in mTORC1 activity was not associated with either
memory deficits or memory augmentation.

When mTORC1 activity was further

elevated by a brain concussion, memory deficits became exacerbated when compared
to injured Tsc2+/+ litter mates. When mTORC1 levels returned to baseline five weeks
after the injury, Tsc2+/KO mice cognitive performance was similar to Tsc2 +/+ litter mates.
My results indicate that acute elevation of mTORC1 activity is detrimental for brain
injury-induced cognitive impairments. This supports previous findings showing that
acute inhibition of mTORC1 with rapamycin improved outcome after brain injury (44,
147).

However, my results were not able to determine if elevated mTORC1, in

Tsc2+/KO mice, would be beneficial in chronic stages after a closed head injury.
Rapamycin and its derivatives are potent inhibitors of mTORC1. The treatment
of mTORC1 related disorders with these drugs has the disadvantage of potential over
inhibition of mTORC1, which can have detrimental health effects (146, 206). This led
to the hypothesis that mTORC1 modulation with nutrients, such as amino acids, could
more subtly produce changes in this pathway.

In chapters 4 and 5, I presented

evidence indicating that glutamine can inhibit in vivo mTORC1 signaling, impairs LTM
and extends the life span of Tsc2CKO mice.

Although the mechanism by which
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glutamine exerts this action is not known, a correlation between its administration and
mTORC1 reduction was shown, indicating that this pathway may, in part, explain
glutamine’s effects. These are important findings that support the idea that mTORC1
could be modulated by designing a specific nutritional program. Indeed, reducing
mTORC1 signaling with rapamycin has been shown to extend lifespan in several
organisms including mammals (46). Likewise, dietary restriction in the absence of
malnutrition is associated with extended longevity, increased stress resistance and
improved metabolic fitness (51). The effects of dietary restriction have been correlated
with lower mTORC1 activity, suggesting that this pathway is involved in lifespan
modulation and can be regulated through nutritional changes (89).

Whether an

optimal range of mTORC1 activity exists that can extend lifespan and enhance
memory is not known.
Glutamine is a non-essential amino acid that becomes essential after trauma.
Its administration can improve survival and diminish infectious complications in
critically ill patients (5).

Future experiments should be designed to test whether

glutamine can improve TBI outcome and if this improvement is associated with
mTORC1 regulation. TBI is associated with an acute hyperglycemic phase which
coincides with MTORC1 increase following the concussion (8, 20, 174).

This is

followed by an extended suppression of glucose metabolism that can be
counterbalanced with sodium pyruvate treatments to improve outcome (50, 133, 134).
Glutamine is indirectly involved in mTORC1 signaling modulation and energy
production through the Krebs cycle (30, 102). Consequently, I would expect glutamine
to be beneficial in the treatment of TBI.
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Taken together, my findings suggest that memory formation can function
normally within a certain range of mTORC1 activation (Fig 6.1). Previous studies have
shown that rapamycin administration can decrease mTORC1 activity and impair LTM,
and results from chapter 4 indicated that mTORC1 inhibition by glutamine
administration produces a similar effect (18, 31, 188). The results from chapter 3
show that a further increase of mTORC1 signaling in Tsc2+/KO mice, after a closed

Figure 6.1: Hypothetical range of mTORC1 activity and its modulation of LTM.
MTORC1 inhibition with rapamycin impairs memory formation, suggesting that low
levels of mTORC1 activity during consolidation can be detrimental for this process.
On the other hand, high levels of mTORC1 activity might produce cognitive deficits,
such as those seen in TSC patients.

Therefore, an optimal range of mTORC1

activation should produce average (as seen in healthy individuals) cognition (red
dotted curve). Whether a fine tuning of mTORC1 activity within its optimal range can
be achieved to improve cognition is not known (Green dotted curve).
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head injury, impaired LTM in these animals. These results suggest that elevated
mTORC1 signaling can also be detrimental for LTM. This is further supported by the
fact that TSC patients also suffer cognitive deficits.
Although our understanding of the mechanisms by which mTORC1 is regulated
is not fully understood yet, my results support the possibility that an optimal mTORC1
activity range exists to successfully modulate LTM. Whether LTM can be enhanced
within this optimal range is still unclear. My results from chapter 3 show that elevated
levels of mTORC1 activity in Tsc2+/KO mice had no effect on memory formation.
However, it has been previously shown that intra-hippocampal infusions of glucose
enhance LTM and increase mTORC1 signaling (31). A better understanding of the
mechanisms by which nutrients modulate mTORC1 would greatly aid in the design of
treatments that can specifically target distinct pathways to finely tune mTORC1
activity.

.
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